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Amyloid fibrils have been implicated in numerous human 
diseases including Alzheimer's disease (AD).  The fibrils found in AD 
are formed by the misfolding and aggregation of the Aβ peptide.  
Amyloid fibrils are potentially important causative agents, but high-
resolution structural information is not yet available.  This research 
analyzes amyloid fibril structure via two different experimental routes.  
In one approach, ELISA techniques were utilized to study the binding 
of available anti-amyloid antibodies to single-residue proline and 
alanine mutant fibrils of Aβ.  Binding to some cysteine and modified 
cysteine mutants was also tested.  These data were compared to fibril 
stability, hydrophobicity change, ThT binding, and changes in fibril 
protection.  There appeared to be no correlation to these, except for 
weak correlation to ThT binding.  The results at specific residues did 
stand out as significant.  WO1 and PGA1 binding appeared to be 
affected by both charge and structural changes at specific residues.  
For WO1, mutations at residues 16, 27, and 28 were shown to have 
the greatest impact on binding.  For PGA1, mutations at residues 27, 
28, 30, 31, and 36 were shown to do so.  Upon closer examination, 
the enhanced binding to mutants at residues 16 and 36 appeared to 
be due to structural changes.  Binding to mutants at residue 27 could 
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be due to structural changes, but these results are not entirely clear.  
Binding to mutants at resides 28, 30, and 31 appeared to be due to 
charge differences.  Binding of WO1 was found to be sensitive to salt 
and pH conditions suggesting electrostatic interactions are important 
to binding.  Mutations in the Aβ sequence have a strong impact on 
binding.  The basis of these results is still not entirely clear, but they 
could be important clues to the nature of fibril structure or the fibril 
epitopes recognized by the antibodies.  Since the number of existing 
antibodies reacting with fibrils is limited, phage display techniques 
were employed to develop new binding reagents with a larger range of 
binding properties for fibrils.  A library of antibody fragments was 
constructed in a phage display system and was selected for members 
with fibril-binding properties.  Although the library was validated, to 
date, no suitable antibodies have been isolated. 
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 Amyloid fibrils have been implicated in numerous human 
diseases.  One of the most prominent of these is Alzheimer's disease 
(AD).  AD is a neurodegenerative disorder characterized by 
progressively worsening dementia.  Affected individuals can suffer 
among other symptoms: memory loss, difficulty in reasoning, 
disorientation, and personality changes.  It is the leading cause of 
dementia and is the most common neurodegenerative disease [1].  For 
the most part, it affects people later in life, though some inheritable 
forms can take effect in mid-life and even earlier.  Indeed, age is the 
greatest risk factor for AD with up to ten percent of people over 65 
and up to fifty percent of people over 85 being affected.  The 
symptoms of AD can be attributed to the extensive neuronal cell death 
associated with the disease.  This cell death and corresponding loss of 
brain function can result in the deaths of affected individuals.  An 
estimated four million Americans are currently afflicted and millions 
more will follow in the coming years [1].  The costs in human suffering 
and medical care make AD a grim and far-reaching disease with 
disastrous socioeconomic consequences.  It is of the utmost 
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importance that we continue to make headway in our efforts to fight 
the disease.  Much is now known about AD, but continuing research 
will be required before the effects of the disease can be effectively 
curbed. 
 
The onset and advancement of Alzheimer’s disease can be 
correlated to the accumulation of the Aβ peptide.  It is a 39 to 43 
amino acid cleavage product from the amyloid precursor protein (APP) 
that can accumulate in the brain.  This relationship is supported by the 
fact that all genes currently known to be connected to familial AD 
influence either Aβ production or deposition [2-4].  Moreover, Aβ(1-
42) and Aβ(1-40) are cytotoxic peptides [5-7].  Some studies indicate 
that increasing levels of insoluble Aβ in the brain relative to the soluble 
form may be directly related to the development of AD [8].  In 
addition, Aβ cytotoxicity has been linked to the ability of the peptide to 
aggregate into amyloid fibrils, which can accumulate in deposits in 
neural tissue [6].  The form of Aβ found primarily in aggressive, early-
onset AD, Aβ(1-42), is much more prone to aggregation than the (1-
40) species of late-onset AD [6, 9].  This suggests that an enhanced 
ability to form amyloid fibrils can lead to a more rapidly progressing 
disease state [6].  Furthermore, amyloid fibrils have been shown to be 
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toxic to neurons [10].  This connection between amyloid fibrils, the 
ubiquitous indicators of AD found in affected neural tissues, and AD 
pathogenesis led to the development of the amyloid hypothesis of AD.  
This theory states that it is the buildup of Aβ in amyloid fibrils that 
leads to the neural tissue degeneration and pathogenesis of AD [11].  
There is much evidence supporting the amyloid hypothesis of AD, but 
there is also evidence pointing away from it. 
 
Some studies suggest the fibrils themselves may not be the 
direct cause of AD pathogenesis [12].  Bearing in mind that insoluble 
Aβ appears to take part in AD pathogenesis, it may be that other 
insoluble Aβ species besides amyloid fibrils are at fault.  Amyloid fibril 
intermediates may actually be responsible for AD pathogenesis [13].  
These intermediates include spherical particles as well as protofibrils 
[14-16].  They may be precursors in the formation of amyloid fibrils 
[14, 16] or they may be the products of distinct assembly pathways 
[14].  The protofibrils are of particular interest since there is some 
evidence suggesting these may be the toxic species.  For instance, the 
‘Arctic’ APP mutation associated with a particular familial form of AD 
has been shown to lead to increased protofibril formation and stability, 
but not increased fibril formation [17].  Because of the possible role of 
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protofibrils in AD pathogenesis, they will be further explored within a 
discussion of amyloid fibrils. 
 
Amyloid Fibrils 
Amyloid fibrils were first discovered in human neural tissue and 
reported by Virchow in 1851 [18].  The name amyloid is a misnomer 
stemming from the fact that a starch staining technique was originally 
used to stain the fibrils.  The word “amyloid” actually means starch-
like.  Virchow used the iodine and sulfuric acid technique for staining 
starches and found that the fibrils stained similar to cellulose [19].  
Though we now know the fibrils are made up of proteins, the name 
amyloid remains in use.  Since that initial discovery, more refined 
techniques have been developed for staining and detecting amyloid 
fibrils. 
 
Congo Red staining was a significant development to that end.  
This dye was found to be a specific and sensitive detector of amyloid 
fibrils by Bennhold in 1922, as it stains the fibrils a bright red [20].  It 
was later discovered by Divry and Florkin that polarizing optics could 
be used to observe amyloid fibrils [21].  With this technique, otherwise 
inconspicuous amyloid deposits in tissue samples can be detected 
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since they show birefringence.  That is, the fibrils have a regular, 
ordered structure capable of altering the phase of incident light 
passing through them.  By combining these two techniques, using 
polarizing optics on fibrils stained with Congo Red, it was found that 
amyloid fibrils have a distinctive green birefringence [22].  The red 
color exhibited by the dye shifts to green under polarizing optics.  
Other than the obvious utility this technique provides, it also 
emphasizes that amyloid fibrils are not amorphous aggregates, but 
rather highly organized structures. 
 
There are many amyloid diseases and conditions in which 
amyloid fibrils are present.  The proteins responsible for the fibrils vary 
from one disease to the next.  In fact, there are at least 20 different 
proteins found in humans that are reported to form amyloid fibrils 
[23].  Though the fibrils in each amyloid disease are composed of 
different proteins, they share many structural characteristics common 
to all amyloid fibrils.  Cohen and Calkins revealed through electron 
microscopy studies that amyloid fibrils of many different proteins share 
a number of common characteristics at the macro scale.  The fibrils 
are highly insoluble, rigid, nonbranching, and of variable lengths up to 
several µm [22, 23].  They are in the vicinity of 8 to 10 nm in 
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diameter and are likely made up of two or more protofilaments 
running in parallel and twisted about one another.  These are in the 
range of about 3 nm in diameter.  Protofilaments and protofibrils are 
separate, distinct species.  Protofibrils have been found to be curved 
fibers 3 to 10 nm wide and up to 200 nm in length [14, 16, 24].  They 
do not approach the lengths reached by amyloid fibrils and are not 
subunits of these fibrils. 
 
X-ray fiber diffraction studies were later conducted on a number 
of different amyloid fibrils to probe the amyloid superstructure.  These 
revealed that amyloid fibrils exhibit a cross-β conformation.  That is, 
the fibrils are rich in β-sheet structure and the β-strands run 
perpendicular to the fibril axis.  In this conformation, the β-strands are 
hydrogen-bonded into β-sheets lying parallel to the fibril axis (Figure 
1).  This particular conformation appears to be rare in nature and is 
more typical of denatured proteins [22].  It has been shown that some 
insect silks exhibit the cross-β conformation, but their β-strands 
usually run parallel to the fibril axis [22].  A comparison is shown in 
figure 1.  Perpendicular β-strands are generally reserved to amyloid 
fibrils.  Protofibrils have also been found to be rich in β-sheet structure 











Figure 1.  The cross-β conformation.  In amyloid fibrils, β-sheets 
lie parallel to the fibril axis.  These are composed of β-strands running 
perpendicular to the fibril axis.  In comparison, insect silks with cross-
β structure possess β-strands running parallel to the fibril axis [22].  
The β-strands are shown forming β-sheets on the front faces of the 





fibrils.  As previously mentioned, these fibrils are found in many 
human diseases. 
 
Other Amyloid Diseases 
The amyloidogenic protein in each amyloid disease is unique.  
Furthermore, the means by which each becomes amyloidogenic can 
differ.  The role of the fibrils in each disease, when it is known, can 
also differ from one disease to the next.  A few examples of diseases 
other than AD marked by the presence of amyloid fibrils are familial 
amyloid polyneuropathy (FAP), secondary amyloidosis, and type II 
diabetes.  These represent a small cross-section of diseases in which 
amyloid fibrils are found.  Briefly looking at each should provide some 
insight into the diverse nature of amyloid diseases. 
 
The culprit protein in FAP is transthyretin (TTR), which is 
normally responsible for transporting retinol-binding protein in addition 
to thyroxine.  Certain mutations in the TTR protein destabilize it such 
that the normally soluble protein can misfold and become prone to 
aggregation [26, 27].  The fibrils of TTR can accumulate in many 
different tissues, but often end up in the heart where the deposits can 
lead to congestive heart failure.  More stable variants of TTR can also 
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aggregate into amyloid fibrils in the heart, but in these cases the 
impact is less severe and the age of onset is later in life [26].  Many 
other diseases can be tied to mutations in fibril-forming proteins [27].  
These include familial early-onset AD, Creutzfeldt-Jakob disease, and 
several others. 
 
Secondary amyloidosis is a condition that occasionally arises in 
response to extended or severe inflammation.  In this disease, the 
amyloidogenic protein is amyloid A (AA), a proteolytic product of the 
circulatory precursor serum amyloid A (SAA) [26].  Fibrils of AA are 
deposited mainly in the spleen, kidneys, and liver where they can 
cause organ failure.  In secondary amyloidosis, severe inflammation 
and tissue damage lead to ramping of SAA production up to 1000 fold 
of basal levels.  It is not known exactly what drives the conversion of 
SAA to AA leading to the deposition of AA fibrils.  However, it has been 
suggested that the disease state results from an inability to clear the 
excess protein [26].  Another amyloid condition marked by protein 
overproduction is light chain amyloidosis [26]. 
 
An example of amyloid as a secondary component of a disease 
occurs in type II diabetes.  The central problem in this disease is 
 10
insulin underproduction and insulin resistance leading to dangerously 
elevated blood glucose levels.  The amyloidogenic protein is islet 
amyloid polypeptide (IAPP), which is normally released into the 
bloodstream concurrently with insulin to regulate blood glucose levels 
[26, 28].  In type II diabetes, IAPP can aggregate into amyloid fibrils 
that are deposited in the pancreas where they can lead to the 
destruction of insulin-producing β-cells.  These fibrils can then 
exacerbate the pathology of this disease by further hampering insulin 
production. 
 
It is clear that amyloid fibrils are pervasive in many human 
diseases.  They are not always the defining characteristic of a given 
disease, such as in type II diabetes, but their impact is nonetheless 
significant and destructive.  Moreover, the constituent proteins in each 
are varied both in their amino acid sequences and in the causes of 
their amyloidogenicity.  Amyloid fibrils have been under scientific 
scrutiny for some time and continue to be studied.  In the history of 
amyloid research, many important findings have been made to 
establish a body of knowledge about these fibrils.   Little detailed 
information about a common amyloid fibril structure is available.  
However, much more is known about the proteins and peptides that 
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misfold to form those fibrils.  The peptide responsible for AD amyloid 
fibrils, Aβ, has been thoroughly studied.  The fibrils found in AD are 
composed primarily of misfolded and aggregated Aβ peptide.  We have 
learned a bit more specifically about these fibrils.  Before discussing 
them, it is first helpful to have a basic understanding of the Aβ 
peptide. 
 
The Aβ Peptide 
 The Aβ peptide is a cleavage product from the APP, which is a 
large transmembrane protein found on the surfaces of cells in many 
different tissues.  The exact functions of APP have not yet been 
established.  Furthermore, it has been shown that deletion of the APP 
gene in mice does not cause early death or a serious disease state 
[29].  It is possible that this could be due to the existence of several 
mammalian homologs to this gene [29].  In any case, APP is 
evolutionarily conserved and expressed in all mammals.  This suggests 
it serves an important role [29].  There are numerous isoforms of APP 
that arise from alternative splicing of the APP gene.  Some such as the 
751 and 770 amino acid isoforms are found in numerous cell types 
while others such as the 695 amino acid isoform are found 
predominantly in neuronal cells.  There is also added variation due to 
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several post-translational modification of APP [9, 29].  APP metabolism 
is still further complicated by variable proteolytic cleavage of the 
extracellular domain.  Though the whole of APP metabolism is quite 
complicated, we are focused only on the products of proteolytic 
cleavage. 
 
APP can be cleaved at specific sites by the α-, β-, and γ-
secretases (Figure 2).  First, either α-secretase cleaves 12 residues out 
from the membrane-spanning domain or β-secretase cleaves 28 
residues out.  This releases the large soluble α- or β-APPs domains, 
respectively.  Only when β-secretase cleavage has occured can γ-
secretase cleavage result in the Aβ peptide.  γ-secretase cleaves about 
12 to 14 residues into the membrane-spanning domain, releasing the 
Aβ peptide [9].  These alternate cleavage patterns are shown in figure 
2.  The peptide can range in length from 39 to 43 residues [30].  The 
43 residue sequence is shown in figure 3.  The 40-residue variant is 
that most commonly found in amyloid fibrils.  A number of studies 




Figure 2.  APP metabolism.  In this example, a 770 residue isoform 
is used.  Cleavage by β-secretase at position 671 followed by γ-
secretase at position 711 to 713 yields the Aβ peptide [9].  (Adapted 
from Selkoe, D.J., Amyloid beta-protein and the genetics of 









Figure 3.  The Aβ(1-43) amino acid sequence.  In the 40-residue 
variant, the amyloid core extends roughly from the vicinity of residue 
15 to that of residue 36.  The remaining amino- and carboxy-terminal 
residues are solution accessible and are not involved in protected β-




 Limited proteolysis and hydrogen-deuterium (HD) exchange 
studies on the 40-residue isoform of Aβ in amyloid fibrils have shown 
the presence of a stable core [31-33].  The remainder of the peptide is 
exposed to digestion and HD (hydrogen-deuterium) exchange.  Only 
about half of the residues of the Aβ peptide are involved in protected 
β-sheet structure in this core.  The remaining residues at the amino- 
and carboxy-terminal ends of the peptide are not involved and are 
accessible to solvent.  These regions span the first 13 to 16 residues at 
the amino terminus and the last 4 residues at the carboxy terminus 
[32, 34].  Aβ protofibrils also possess a protected core, though the 
degree of protection is less [13].  This suggests that protofibril 
structure may be similar to that of fibrils.  The presence of a stable 
core in amyloid fibrils is further supported by stability studies on fibrils 
of single proline mutants of Aβ [34]. 
 
Scanning proline mutagenesis was used in conducting these 
experiments [34].  This technique entails generating single proline 
mutants at each position in the Aβ sequence and growing fibrils from 
the mutants to be analyzed [34, 35].  These mutants can be very 
informative since the rigid nature of proline and the fixed angle bend it 
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imparts to the peptide can have a significant impact on a given protein 
structure.  Prolines are expected to have little impact on unstructured 
regions and less impact on turn regions when compared to that on β-
sheets [34].  In fact, prolines are not usually found in amino acid 
sequences involved in β-sheet structure where they appear to be 
highly disfavored [34, 36, 37].  Prolines are more amenable to 
unstructured regions and turns that are capable of incorporating the 
rigid amino acid without being distorted.  For these reasons, prolines 
are expected to destabilize fibrils when inserted into positions involved 
in β-sheet structure [34]. 
 
Fibrils from mutant peptides with proline in the amino- and carboxy-
terminal regions share, for the most part, stabilities similar to those of 
wild-type fibrils.  Fibrils from mutants in the core sequence are 
destabilized to varying degrees [34].  It is the amyloid core that is 
involved in fibril formation and the protected nature of it once 
incorporated into fibrils highlights the stability of amyloid fibrils.  In 
addition to the residues involved in fibril formation, more is known 
about Aβ amyloid fibrils.  This information has been applied to build a 
model of amyloid fibril structure.  Our model describes the structure of 
Aβ protofilaments, the constituents of Aβ amyloid fibrils.  It is based 
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on the aforementioned data, particularly the scanning proline 
mutagenesis and fibril stability results [34].  The model is shown in 
figure 4.  It predicts a tightly packed amyloid core with the 
unstructured, solvent accessible amino- and carboxy-terminal regions 
projecting out from it.  It is not certain that these regions are 
unstructured, but their high degree of solvent accessibility suggests 
they are not involved in the tightly packed and protected β-sheet 
structure of the amyloid core [31-33].  With that said, the core is the 
focus of the model. 
 
The model is organized as a parallel β-helix, a structure 
consisting of β-strands coiling down its length and forming β-sheets 
between parallel β-strands [34].  In the model, the Aβ rungs are 
stacked in register down its length [34].  Each Aβ subunit within 
contains three β-strands separated by two turns forming roughly a 
triangle (Figure 4).  The turns are in the vicinity of residues 22 to 23 
and 29 to 30 resulting in three β-strands that are 5 to 7 residues in 
length: 15-21, 24-28, and 31-36.  The core β-sheet structure ends in 
the region of residues 15 to 16 and 36 to 37.  From these regions, the 
solvent accessible amino- and carboxy-termini extend out from the 








Figure 4.  Aβ amyloid protofilament model.  Aβ monomers are 
stacked down the length of the filament with residues 1-14 and 37-40 
extending in disorder out from the amyloid core.  Residues 15-21, 24-
28, and 31-36 comprise β-strands.  Residues 22-23 and 29-30 
comprise turn regions [34].  (Adapted from Williams, A.D., et al., 
Mapping abeta amyloid fibril secondary structure using scanning 




though it is not set in stone.  As further research is conducted, the 
model will continue to grow and evolve.  The research presented here 
represents an effort to further our understanding of amyloid fibril 
structure.  Towards that goal, ELISA techniques have been used to 
study the binding of anti-amyloid antibodies to amyloid fibrils. 
 
Anti-amyloid Antibodies 
There are several anti-amyloid antibodies available in our lab 
[40].  They are all of the IgM class, a pentameric species with ten 
antigen-binding sites and a molecular weight of around 900 kDa [38].  
IgM antibodies are the products of the primary immune response.  
They are the first antibody species produced in response to a given 
antigen.  Production of antibodies of other classes, including IgG, 
requires a class switch event involving gene rearrangements to take 
place [38].  IgG antibodies are the products of the secondary immune 
response after the class switch event.  The IgM molecule is composed 
of five IgG-like subunits [38].  A diagram of the IgM molecule is shown 
in figure 5e.  The subunits resemble IgG molecules in structure (Figure 
5a).  Each subunit possesses one µ heavy chain and one light chain 
held together by disulfide bonds.  The heavy chain contains four 






Figure 5.  Major immunoglobulin classes.  IgM class antibodies (e) 
are pentameric species when compared to IgG class antibodies (a).  
They possess ten binding sites compared to two for IgG molecules 
[38].  (Adapted from Kuby, J., Immunology. 3rd Edition ed. 1997.) 
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(Figure 5e).  The light chain contains one constant domain, CL, and 
one variable domain, VL (Figure 5e).  The IgG-like subunits are held 
together by disulfide bonds and additionally by a small polypeptide 
called the J chain between two of the subunits (Figure 5e).  Each of 
the ten antigen-binding sites is comprised of six complementarity 
determining regions (CDRs) looping out from the two variable 
domains, three from the heavy chain and three from the light chain 
[39].  These loops are responsible for antigen binding and amino acid 
differences between them provide for binding diversity.  In IgM 
molecules, the multiple binding sites can bind cooperatively to an 
antigen provided there are a sufficient number of target sites on the 
antigen.  Because each binding site contributes to the overall affinity, 
its individual affinity need not be as strong.  This is the avidity effect.  
In the case of amyloid fibrils, the apparently regular, repeating 
structure could potentially accommodate multivalent binding [40].  
The avidity effect may be important to amyloid binding.  This may 
explain why, to date, we have only obtained IgM antibodies. 
 
Two well-studied anti-amyloid antibodies are WO1 and WO2, 
isolated by Dr. Brian O’Nuallain [40].  These antibodies possess κ light 
chains.  They have been shown to possess germ-line sequences by 
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sequence analysis (Kimberly Salone, unpublished data).  That is, the 
WO1 and WO2 sequences are made up of genes already encoded in 
the genome and contain variable regions that have not been altered by 
somatic mutation.  The antibodies were isolated from mice immunized 
with Aβ amyloid fibrils.  Monoclonal antibodies were selected so that 
they bind only amyloid fibrils and not Aβ monomer.  This was done by 
carrying out binding to immobilized Aβ amyloid fibrils in the presence 
of soluble Aβ monomer.  The antibodies were isolated from high-
density mouse myeloma cultures.  These antibodies also bind amyloid 
fibrils other than Aβ including amyloids from immunoglobulin light 
chain, transthyretin, and β2-microglobulin.  This binding of different 
targets by the antibodies is very unusual and supports the notion of a 
common structural motif among all amyloid fibrils.  Furthermore, the 
apparent structural specificity makes these antibodies very useful in 
studying amyloid structure.  WO1 has recently been shown to bind Aβ 
protofibrils as well (Dr. Merav Geva, unpublished data).  This result 
coupled with the other characteristics shared between amyloid fibrils 
and protofibrils indicates that these two species may be structurally 
related.  A study of amyloid fibril structure may provide some insight 
into protofibril structure as well. 
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There are limits in the use of the anti-amyloid antibodies.  A 
major limitation is that all of these anti-amyloid antibodies are of the 
IgM class.  Since these are large, flexible, multivalent species, they are 
poorly suited for many structural studies.  For instance, no IgM 
molecules have yet been crystallized.  Due to such limitations, another 
goal of this thesis work has been to generate novel anti-amyloid 
antibodies more suitable for these studies.  To this end, phage display 
techniques have been applied. 
 
Phage Display Principles 
For our study, phage display was used to generate amyloid-
specific Fab antibodies more amenable to structural work.  Phage 
display is a powerful technique that can be used for the affinity 
selection of specific proteins or peptides out of a massive library.  Such 
a library can exceed sixty billion unique peptides or antibody forms 
allowing for sampling of a broad range of potential binders to a given 
target.  Furthermore, the selection process is much faster than 
traditional hybridoma screening and can be completed in a relatively 
short period of time [41].  Phage display involves two major steps.  
The first step is the expression of a library of proteins or peptides as a 
fusion protein with one of the phage coat proteins.  This results in a 
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phage library whose constituents each have mutant proteins or 
peptides expressed on its coat.  The number of copies depends on the 
phage display system used.  The second is the affinity selection of the 
phage library for a given target.  Phage expressing proteins or 
peptides with high affinity for the substrate can be separated from 
those with low or no affinity simply by binding the phage to the target 
and washing away unbound phage.  In order to better understand 
exactly how this process works, one must first understand the M13 
bacteriophage that is used in phage display experiments. 
 
The M13 bacteriophage is a filamentous phage that infects E. coli 
by interacting with the F pili found on F+ cells through its five tail 
fibers.  It is used in phage display for several reasons.  The structure 
and life cycle of M13 are well understood [42].  It is easy to work with 
and manipulate as is the host, E. coli.  It does not kill the cells after 
infection, but only slows their growth, allowing production of large 
amounts of phage by simply culturing infected cells.  The phage 
particles are extremely hardy, resistant to low and high pH as well as 
other denaturants.  Several of the phage coat proteins will tolerate the 
addition of sequences of peptides or small proteins without disruption 
of their structures or that of the phage particle [41].  This is key to the 
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phage display technique.  When DNA is added to the phage genome 
making it longer, the phage particle simply incorporates more of the 
major coat protein to encompass the added DNA inside the phage 
filament [41].  The M13 phage is a robust and versatile tool that can 
easily be manipulated for use in phage display experiments.  A 
discussion of the phage structure and life cycle will shed more light on 
these advantages and on the inner workings of the phage display 
technique. 
 
The M13 phage particle consists of a protein coat encapsulating 
a circular single-stranded DNA (ssDNA) genome.  The genome encodes 
the genes for eleven proteins, five of which comprise the phage coat 
and five of which are nonstructural proteins involved in viral 
replication.  Gp8 is the 5kDa major coat protein with about 2700 
copies per wild-type phage particle (Figure 6, top).  It serves to 
encapsulate the phage genome.  Five copies each of gp3 and gp6 are 
found at one end of the particle and five each of gp7 and gp9 at the 
other.  Gp3, the tail fiber protein, and gp6 are involved in the infection 
process.  Gp7 and gp9 recognize a packaging signal in the phage 
genome and are necessary for formation of the mature phage particle 








Figure 6.  A diagram of the M13 bacteriophage.  The phage 
protein coat encapsulating the phage genome is shown at the top.  In 
the bottom left is a subdomain breakdown of the gp3 coat protein, also 
called pIII.  Gp3 consists of three domains separated by flexible 
glycine-rich linkers: the amino terminal domain (N1), the middle 
domain (N2), and the carboxy-terminal domain (CT) [41].  (Adapted 





sequence to be displayed, but each coat protein has limitations as to 
how it can be modified [41].  Gp3 is the most commonly modified coat 
protein in phage display experiments and presents the fewest 
complications.  Gp3 was modified for this work. 
 
Gp3 consists of three domains separated by flexible glycine-rich 
linkers: the amino terminal domain (N1), the middle domain (N2), and 
the carboxy-terminal domain (CT) (Figure 6, bottom).  N1 and N2 are 
involved in the process of viral infection while CT is involved in phage 
coat structure [42].  Any of the three can be deleted or modified for 
phage display experiments, however CT is typically not modified due 
to the potential for disruption of phage coat structure [41].  N1 was 
replaced with the mutants for this work.  The domain replacement  
effectively eliminates the ability of the transgenic gp3 to be involved in  
the infection of a bacterial host.  If all five copies of gp3 were 
modified, the phage would be incapable of infecting the bacterial host.  
This is a problem when it comes to proliferation of the selected mutant 




Phagemid vectors are phage genomes propagated in the form of 
plasmids that contain a number of modifications.  They possess only 
the transgenic phage coat protein gene and none of the other ten  
genes (Figure 7, top left).  Phagemid vectors, therefore, cannot direct 
the production of phage particles on their own.  They possess the M13 
origin of replication and a functional phage-packaging signal just as 
wild-type phage.  They also have a bacterial plasmid origin of 
replication and an antibiotic resistance marker.  This plasmid structure 
allows phagemid amplification in E. coli cells and selection for 
transfected cells via an antibiotic.  When phagemid vectors are 
transformed into E. coli cells, they are replicated as plasmids and do 
not induce the production of phage particles [41].  Helper phage must 
be introduced to help production of phage particles. 
 
Helper phage are essentially wild-type phage capable of normal 
infection all but for a few important differences.  They have drastically 
reduced proliferation potential due to an altered phage-packaging 
signal that is poorly recognized during phage assembly.  Helper phage 
particles can still be produced, albeit at a much slower rate and titer 
than phage with wild-type packaging signals.  When E. coli carrying 




Figure 7.  A diagram of phagemid display.  E. coli cells infected 
with the phagemid are coinfected with helper phage.  The phagemid 
only provides the one capsid protein gene, which is a fusion with a 
displayed protein gene.  The helper phage genome provides all the 
other genes necessary to produce phage particles.  It also provides the 
nonmutant form of the gene present in the phagemid.  These result in 
chimeric phage particles, with proteins encoded by both the phagemid 
and helper phage genome [41].  (Adapted from Hoess, R.H., Protein 




proteins from both types.  Since the helper phage carry a different 
antibiotic resistance marker than the phagemid vectors, kanamycin in 
the case of the VCSM13 helper phage, E. coli cells can be selected for 
possession of both markers.  This prevents the uninfected cells from 
out-competing the slower growing helper phage infected cells.  The 
helper phage genome guides the production of all the necessary phage 
proteins while the phagemid genomes produce the transgenic tail fiber 
proteins.  This results in the production of chimeric phage particles 
(Figure 7, bottom).  Either a phagemid vector or a helper phage 
genome will be packaged into each phage particle.  Since the helper 
phage genome has a substantially reduced capacity to be packaged 
into phage particles, the vast majority of the particles will contain 
phagemid vectors.  Moreover, each will bear a combination of 
transgenic and wild-type copies of the altered coat protein.  There are 
five copies of gp3 per phage particle, part of which will be transgenic 
and the rest wild-type.  The number of copies of each can be 
controlled somewhat by adjusting the ratio of infecting helper phage to 
phagemid vectors present in the cells.  The ratio can be skewed 
tremendously towards helper phage so most of the phage particles 
contain either one copy or no copies of the transgenic gp3.  The 
particles with no copies of the transgenic gp3 are of no value, but they 
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can be selected against so they are likewise not a burden.  However, 
the particles with one copy will present the transgenic gp3 while 
retaining infectivity since they have four copies of wild-type gp3 [41].  
Having discussed how the M13 bacteriophage and its variants, the 
phagemid vector and helper phage, function in a phage display 
system, it is next important to discuss how a library of phagemid 
vectors is generated. 
 
A cDNA library of mutants must be generated before phage 
display experiments can be carried out.  This can be done with some 
form of random mutagenesis on a starting cDNA sequence.  Error 
prone PCR is one method that can be used.  This technique is simply a 
PCR reaction of the sequence using conditions that result in random 
base substitutions.  It relies on the use of different concentrations of 
manganese and skewed dNTP concentrations in the PCR reaction to 
increase the frequency of these mutations.  The specific PCR conditions 
used will be discussed later.  Once the population of mutant cDNA 
sequences is acquired, it must be cloned into the M13 phage genome 
as part of one of the phage coat protein genes.  This process will be 
discussed in detail later. 
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The phage particles produced through phagemid display present 
the mutant proteins or peptides on their coats.  They can be selected 
for the ability of the displayed mutant to interact with a specific 
substrate.  Furthermore, since the phage particles contain the DNA 
sequences of the mutants, the binding ability of each phage can be 
coupled to the mutant DNA sequence it possesses.  Therein lies the 
power of phage display.  Because the binding ability is associated with 
the DNA sequence, mutant genes coding for strong or weak binders 
can easily be isolated, amplified, and characterized.  This can be done 
entirely without any special knowledge of the target or the means by 
which the mutants may bind it.  Phage display does not depend on a 
knowledge of the intricacies of binding.  It simply samples through a 
huge library of possibilities to find those that have the desired 
properties.  This is a boon to studies involving poorly characterized or 
difficult to study substrates and it allows phage display to cover broad 






There is little detailed information available about a common 
amyloid fibril structure.  We are left with the only concrete information 
being the macroscopic structural cues.  There is somewhat more 
known about Aβ amyloid fibrils, but a detailed molecular structure 
remains elusive.  A working model of Aβ amyloid has been developed 
[34], but further investigation is required to test that model.  The work 
described herein aims to probe deeper into amyloid fibril structure by 
studying the binding properties of anti-amyloid antibodies. 
 
Section 1.  Anti-amyloid Antibodies 
Determining Antibody Binding Properties 
ELISA techniques were used for determining antibody binding 
affinity to amyloid fibrils.  An ELISA experiment involves coating the 
wells of a polystyrene assay plate with a target antigen and 
determining if or how strongly a particular antibody binds to the 
antigen.  This is done by first incubating the coated plate with the 
antibody in question, the primary antibody.   The plate is next 
incubated with a secondary antibody that binds to the primary 
antibody.  The secondary antibody is a conjugate that provides for a 
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means of detection.  Biotinylated secondary antibodies were used in 
this protocol.  These will bind streptavidin-conjugated molecules.  
Streptavidin-Europium was used as the labeling agent for detection of 
anti-amyloid antibodies binding to substrates.  Time-resolved 
fluorescence was used for detecting the Europium.  This technique 
relies on the very long lag time between the excitation and 
fluorescence of Europium.  By the time Europium fluoresces, 
background fluorescence from most all other compounds has decayed.  
Europium also exhibits a large Stokes shift with the excitation and 
emission wavelengths of Europium at 340 and 615 nm, respectively.  
These qualities make Europium a very sensitive and specific vehicle for 
detection.  The ELISA techniques used in these experiments have been 
well established [40].  A diagram of the ELISA protocol is shown in 
figure 8. 
 
In brief, 96-well high-binding polystyrene ELISA plates with flat-
bottom wells (Corning/Costar) were coated using 50 to 100 ng of Aβ 
amyloid fibrils or other aggregates per well.  The fibrils were 
suspended in 50 µL of 1xPBS (Fisher, Appendix I) in each well.  A 
working suspension of 1 µg/mL to 2 µg/mL of the fibrils was prepared 











Figure 8.  A diagram of the ELISA protocol.  This figure shows one 
ELISA plate well.  Plates coated with amyloid fibrils are incubated with 
a primary antibody, a biotinylated secondary antibody, and then 
streptavidin-Europium.  An enhancement solution is added to the wells 




dilution series (Figure 9).  The plates were incubated overnight at 
37°C uncovered to allow the solutions to dry in the wells. 
 
The plates were washed 2 times with ELISA wash buffer 
(Appendix I) to remove dried salts and unbound fibrils.  To block the 
plates, each well was filled with 250 µL of ELISA blocking solution 
(Appendix I).  The plates were covered with plate sealers (Costar) and 
incubated at 37°C for 1 hour.  The plates were emptied and 100 µL of 
ELISA blocking solution was pipeted into each well.  A 400 to 800 nM 
solution of the antibody to be tested was prepared in ELISA blocking 
solution.  100 µL of the antibody preparation was transferred into well 
A1, making 200 µL in total in the well, and pipeted up and down 4 
times to mix (Figure 9).  This process was continued down column 1, 
then from well H1 to well A2, and down thru well F2.  For each step, 
100 µL of the mixture was transferred to the next well in the series 
and mixed as before.  The remaining 100 µL at the end of each dilution 
series was discarded.  The last 2 wells of each dilution series were left 
with only ELISA blocking solution in them.  This process generates a 
dilution series decreasing by a factor of 2 per well, with the last 2 wells 
providing background readings since they contain no primary antibody.  












Figure 9.  ELISA plate layout.  Dilution series are set up down pairs 
of columns.  An example dilution series in columns 1 and 2 would 
begin with the highest concentration in well A1.  Each well down the 
column would have one half the concentration of the previous well.  
The series would continue from well H1 to well A2 and down through 




remove background binding of the secondary antibody and 
streptavidin-Europium from the affinity calculation.  The process was 
repeated for each dilution series.  The plates were covered with plate 
sealers and incubated at 37°C for 1 hour.  When buffer effects on 
binding were to be analyzed, the appropriate buffers were used in 
place of ELISA blocking solution for the primary antibody-binding step 
(Table 1).  For the remainder of the protocol, ELISA blocking solution 
was used in all cases. 
 
The plates were washed 2 times with ELISA wash buffer.  A 
1:5000 dilution of the secondary antibody, biotinylated goat anti-
mouse IgM (µ-chain specific, Sigma), was prepared in ELISA blocking 
solution.  100 µL was pipeted into each well.  The plates were covered 
with plate sealers and incubated at 37°C for 40 minutes.  The plates 
were washed 2 times with ELISA wash buffer.  A 1:1000 dilution of 
Delfia Europium-labeling streptavidin (Perkin Elmer) was prepared in 
ELISA blocking solution.  100 µL was pipeted into each well.  The 
plates were covered with plate sealers and incubated at room 
temperature in the dark for 1 hour.  The plates were washed 3 times 







Table 1.  Buffers for salt and pH effects experiments.  All buffer 
compounds except citric acid were ordered from Calbiochem.  The first 
3 buffers in the table were used for testing the effects of the amount 
of salt.  The first 5 buffers excluding the third were used for testing the 
effects of different cations and anions.  HEPES is a buffer of very low 
ionic strength, so it should not interfere greatly with comparing the 
different salts.  Na2HPO4 has roughly double the ionic strength of the 
other 2 salts so it was used at half the concentration for a balanced 
comparison.  The last 8 buffers were used for testing pH effects.  
 
Buffer compound Salt pH 
5 mM HEPES - 7.5 
5 mM HEPES 150 mM NaCl 7.5 
5 mM HEPES 600 mM NaCl 7.5 
5 mM HEPES 150 mM KCl 7.5 
5 mM HEPES 75 mM Na2HPO4 7.5 
5 mM citric acid 150 mM NaCl 3.0 
5 mM citric acid 150 mM NaCl 5.8 
5 mM PIPES 150 mM NaCl 5.8 
5 mM PIPES 150 mM NaCl 7.4 
5 mM Bicine 150 mM NaCl 7.4 
5 mM Bicine 150 mM NaCl 8.5 
5 mM CHES 150 mM NaCl 8.5 
5 mM CHES 150 mM NaCl 10.0 
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(Perkin Elmer) was pipeted into each well.  The enhancement solution 
chelates Europium from the complexes and into solution for detection.   
A Wallac Victor2 1420 Multilabel Counter was used for detection.  Each 
reading was taken for 400 µs after a 400 µs delay (Perkin Elmer). 
 
 The binding data were analyzed using Microsoft Excel and 
plotted as sigmoid curves in Kaleidagraph.  The fluorescence counts for 
each assay were all divided by 4,800 counts/fmol to obtain the 
femtomoles of Europium in each well.  These values were plotted 
against –log10(antibody concentration) at each point to obtain sigmoid 
curves (Figure 10).  Two key features of these curves are the 
magnitude and the midpoint of the sigmoid curve (Figure 10).  The 
magnitude is indicative of the number of available antigen binding 
sites while the midpoint tells the affinity of the antibody for the 
antigen. 
 
 After preparing the binding data as described, it was plotted in 
Kaleidagraph against log10(antibody concentration).  Sigmoid curve fits 
were obtained using equation 1 in Kaleidagraph.  The binding affinity 
from each curve was obtained from the inverse log of the x value at 








Figure 10.  An example of ELISA data.  These curves show the 
binding of WO1 to Aβ amyloid (open circles), fibrils of antibody light 
chain (JTO5, closed squares), and a control IgM (open triangles) [40].  
The midpoint of the Aβ amyloid sigmoid is denoted by the red lines.  
The binding affinity is obtained by getting the inverse log (10x) of the x 
value at that point.  (Adapted from O'Nuallain, B. and R. Wetzel, 
Conformational Abs recognizing a generic amyloid fibril epitope. Proc 
Natl Acad Sci U S A, 2002. 99(3): p. 1485-90.) 
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(Equation 1).  The binding affinity is the antibody concentration at 
which one half maximal binding is reached.  This value is reported as a 
molar concentration (M). 
y = m3 / (1 + e^((m1 – m0) / m2)).  Equation 1. 
This equation was entered into Kaleidagraph.  The starting 
values were: m1 = 1, m2 = 1, and m3 = 20.  After the best fit 
sigmoid was calculated in Kaleidagraph, values were returned for 
m1, m2, and m3.  The midpoint x value of the sigmoid was 
reported in m1, the slope of the tangent line to the midpoint was 
reported in m2, and the magnitude of the sigmoid was reported 
in m3.  For determining antibody binding affinity, m1 was used.  




Determining Antibody Concentration 
ELISA techniques were used for determining antibody 
concentration.  The protocol shares many similarities with that for 
determining binding affinity, but there are several important 
differences.  The purpose was to determine concentration rather than 
binding activity, so the ELISA plate was coated with a capture antibody 
rather than amyloid fibrils.  The antibodies whose concentrations are 
to be tested are diluted significantly and all to the same level as a 
standard antibody of known concentration.  The capture antibody will 
bind these antibodies to the plate with very high affinity.  From this 
stage on, the protocol was the same as that for determining binding 
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activity.  After the protocol is completed, the concentrations of the 
unknowns are calculated relative to the known standard. 
 
For this protocol, 96-well high-binding polystyrene ELISA plates 
with flat-bottom wells (Corning/Costar) were used.  They were coated 
using a 1:1000 dilution of a capture antibody, goat anti-mouse IgM (µ-
chain specific, Sigma).  50 µL was pipeted into each well.  Two 
columns were coated for each antibody to be assayed along with an 
additional 2 columns for a control antibody.  The plates were covered 
with plate sealers and incubated at 37°C for 1 hour.  They were 
washed 2 times with ELISA wash buffer.  To block the plates, each well 
was filled with 250 µL of ELISA blocking solution.  They were covered 
with plate sealers and incubated at 37°C for 1 hour. 
 
The plates were emptied and 100 µL of ELISA blocking solution 
was pipeted into each well.  1:100 dilutions of the antibodies to be 
tested were prepared in ELISA blocking solution.  Likewise, a 1:100 
dilution of the standard antibody was prepared.  If any of the resulting 
data sets did not produce a complete sigmoid curve, the initial dilution 
was adjusted when repeating the experiment.  Mouse IgM 
(Calbiochem) was used as the standard since the unknowns were 
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mouse IgM antibodies.  It is imperative that the concentration of the 
standard antibody be known since it is later used in calculating the 
concentrations of the antibodies of interest.  100 µL of the antibody 
preparation was transferred into well A1, making 200 µL in total in the 
well, and pipeted up and down 4 times to mix (Figure 9).  This process 
was continued down column 1, then from well H1 to well A2, and down 
thru well F2.  For each step, 100 µL of the mixture was transferred to 
the next well in the series and mixed as before.  The remaining 100 µL 
at the end of each dilution series was discarded.  The last 2 wells of 
each dilution series were left with only ELISA blocking solution in 
them.  This process generates a dilution series starting at a 1:200 
dilution and decreasing by a factor of 2 per well with the last 2 wells 
providing background readings since they contain no primary antibody.  
The process was repeated for each antibody including the standard 
antibody.  The plates were covered with plate sealers and incubated at 
37°C for 1 hour.  The remainder of the protocol is already described 
under the heading ”Determining Antibody Binding Properties” starting 
at the secondary antibody incubation step. 
 
 The resulting data were analyzed using Microsoft Excel and 
plotted as sigmoid curves using Kaleidagraph.   For each concentration 
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determination experiment, a sigmoid curve fit for the standard 
antibody was obtained using equation 1 in Kaleidagraph.  The m1, m2, 
and m3 values were collected from the sigmoid fit results.  Before 
proceeding further, the other antibody data had to be checked for 
consistency.  To do so, sigmoid fits were obtained for each of the other 
sets of antibody data.  The antibody concentrations from the standard 
antibody were substituted for these curves since their concentrations 
were still unknown at this stage.  The purpose of these sigmoid fits 
was to make sure the magnitudes of all the curves are comparable to 
the standard curve.  Therefore, the only the relevant value from these 
curves is the magnitude, m3.  Generally, they are very close within the 
same experiment.  If they are not, then aberrant curves should be 
scaled to have the same magnitude as the standard curve.  This 
simply requires multiplying each y value of the unknown by the ratio 
of the standard curve magnitude to the aberrant curve magnitude.  If 
this scaling is not performed, the calculated concentration will be 
wrong. 
 
To calculate the concentration of an unknown, a y value was 
selected from the middle linear segment of the sigmoid curve data.  y 
values as near the midpoint of the curve as possible were selected 
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(Figure 10, red lines).  The y value along with the initial antibody 
dilution factor, the dilution factor at the selected data point, and the 
sigmoid fit data from Kaleidagraph were all entered into equation 2.  
This equation yields the concentration of the unknown antibody.  The 
calculation was repeated with multiple y values from the linear 
segment.   This served to verify the concentration results and obtain 
greater accuracy. 
Concentration = d*2^w*10^(-m2*ln((m3-y)/y)+m1)  Equation 2. 
The reported concentration is molar (M).  d is the initial dilution 
factor of the unknown antibody, 100 in this protocol.  w is the 
well number in the middle linear segment of the sigmoid curve 
selected for concentration determination.  It is not the number 
from the ELISA plate, but rather the number of the dilution step 
in the series.  For example, w would be 9 for well A2 in figure 9.  
y is the activity, y value measured in fmoles of Europium, in the 
selected well.  ln is natural log.  m1, m2, and m3 are the values 




 Reduced IgM (rIgM) fragments of WO2 were generated for use in 
antibody fragment binding assays.  The rIgM fragment is similar to a 
reduced IgG in that it consists of one heavy and one light chain only 
(Figure 5).  It is a monovalent fragment of the IgM molecule.  That is, 
it possesses only one binding domain.  A reduction and alkylation 
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protocol was used to separate the fragments at disulfide bonds and 
subsequently alkylate the cysteines preventing reassociation (Pierce). 
 
 Before fragmentation, the WO2 sample was purified with an IgM 
purification column, HiTrap IgM Purification HP (Amersham Pharmacia 
Biotech), using the provided protocol.  The following reduction and 
alkylation protocol was adapted from the Immunopure IgM 
Fragmentation Kit (Pierce).  500 µL of a 1 to 2 mg/mL WO2 sample 
was transferred into a 1.5 mL microcentrifuge tube along with 36 µL of 
42 mg/mL 2-mercaptoethanolamine, and 500 µL of 50 mM Tris pH 8.0.  
The final concentration of 2-mercaptoethanolamine should be 1.5 
mg/mL.  This concentration is intended to reduce the WO2 to rIgM 
fragments without further reduction to separate heavy and light 
chains.  The reaction was incubated for 30 minutes in a 37°C water 
bath.  At the end of this time, 65 µL of 123 mg/mL iodoacetic acid was 
added to a final concentration of 8 mg/mL.  The reaction was 
incubated for 15 minutes at room temperature in the dark.  Iodoacetic 
acid alkylates sulfhydryl groups on cysteines, preventing them from 
reforming disulfide bonds.  When this reaction was complete, the 
sample was injected into a 3 mL capacity dialysis cassette of 3 kDa 
MW cutoff (Pierce).   It was dialyzed overnight at 4°C against 1xPBS 
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with 0.02% sodium azide added as a preservative.  Fragmentation was 
verified by running a nonreducing PAGE gel of the sample. 
 
Section 2.  Phage Display 
The pComb3X Phagemid Vector 
The pComb3X phage display vector was used for the phage 
display work described herein.  It was obtained from the Barbas 
laboratory [42].  This vector is approximately 3.4kb in length, 
excluding the SfiI-flanked Fab DNA segment.  This segment is 
approximately 1.5kb in length [42].  This vector has numerous 
properties desirable for phage display experiments [42].  A breakdown 
of the characteristics of this vector is shown in figure 11.  The vector 
imparts ampicillin / carbenicillin resistance to E. coli cells possessing it.  
This allows for simple selection of infected cells.  The gene encoding 
the fusion protein in the plasmid possesses a few important additions.  
The ompA and pelB signal peptides direct the secretion of the light and 
heavy chains, respectively, into the bacterial periplasm.  This becomes 
useful when expression of soluble Fab protein is desired.  There is a 
hexahistidine tag (H6) useful for nickel-affinity purification of the Fab 
protein.  There is a hemagglutinin (HA) tag which allows for detection 
of the Fab using anti-HA antibodies.  There is an amber codon useful  
 
 
Figure 11.  The pComb3X phagemid display vector.  This vector is 
approximately 3.4kb in length, excluding the SfiI-flanked Fab DNA 
segment [42].  This segment is approximately 1.5kb in length.  The 
diagram shows the region immediately flanking the antibody genes.  
lacZ is the promoter.  Shine-Dalgarno (SD) sequences, which help to 
bring the mRNA initiation codon to the ribosome, precede each gene.  
SfiI, SacI, XbaI, XhoI, SpeI, and NheI are restriction sites.  ompA and 
pelB are leader sequences that encode signal peptides directing 
protein secretion into the periplasm.  VL and CL are the variable and 
constant domains of the antibody light chain, respectively.  VH and CH1 
are the variable and constant domains of the antibody heavy chain, 
respectively.  H6 is a hexahistidine tag.  HA is a hemagglutinin tag.  
The amber codon is a stop codon that is suppressed in certain cell 
strains.  trp is the transcription terminator.  (Adapted from Barbas, 
C.F., 3rd, et al., Phage Display: A Laboratory Manual. 2002.) 
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for controlling expression of the fusion protein.  This codon allows for 
this control because of the way different bacterial strains interpret it.  
In suppressor strains, this codon is interpreted as an amino acid and 
results in expression of the full-length fusion of the Fab heavy chain 
and phage gp3 fragments.  In nonsuppressor strains, it is interpreted 
as a stop codon.  This results in expression of the heavy chain without 
the phage gp3 fragment (Figure 11).  Both the heavy and light chains 
are exported to the periplasm.  The oxidizing environment there 
facilitates the association of the two chains via disulfide bonding 
(Figure 11).  This allows for soluble expression of Fab protein. 
 
PCR Random Mutagenesis 
The goal of the phage display experiments was to generate a 
library of antibody fragments and select for those with amyloid-binding 
properties.  PCR random mutagenesis was used to generate the 
starting library.  Before beginning this procedure, a stock of the 
starting phagemid clone was prepared since only a very small amount 
was available.  The starting clone was pComb3XTT provided by the 
Barbas laboratory [42].  Electrocompetent E. coli cells (XL1-Blue, 
Stratagene) were transformed with the pComb3XTT vector.  Before 
transformation, the received pComb3XTT vector preparation and an 
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electroporation cuvette (Gene Pulser Cuvette, BIO-RAD) was placed on 
ice for 10 minutes.  Just before transformation, a tube of 100 µL of 
XL1-Blue cells was thawed on ice.  0.5 µL of the received pComb3XTT 
vector preparation was added to the tube of thawed cells and mixed by 
pipeting up and down.  The tube was incubated on ice for 1 minute.  A 
200 µL pipet tip with the end snipped off was used to transfer the cells 
to the electroporation cuvette.  The cuvette was transferred to a BIO-
RAD Gene Pulser and electroporation was carried out at 2.5 kV, 25 µF, 
and 200 Ω.  A time constant of 4.0 to 4.5 is expected.  Anything 
outside this range indicates likely failed electroporation, possibly due 
to presence of too much salt.  The cuvette was flushed immediately 
after electroporation with 1 mL followed by 2 flushes with 2 mL of 
room temperature SOC medium.  These flushes were combined into a 
50 mL polypropylene tube.  This culture was shaken at 225 rpm for 1 
hour at 37°C in a New Brunswick Scientific C25 Incubator Shaker. 
 
10 mL of SB medium, 3 µL of 100 mg/mL carbenicillin, and 30 
uL of 5 mg/mL tetracycline was added to the culture.  Carbenicillin 
selects for cells carrying the phagemid.  The 15 mL culture was shaken 
at 225 rpm for 1 hour at 37°C.  4.5 µL of 100 mg/mL carbenicillin was 
added and the culture was shaken for another hour.  The culture was 
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transferred to a 1 L Erlenmeyer flask.  185 mL of prewarmed (37°C) 
SB medium, 92.5 µL of 100 mg/mL carbenicillin, and 370 µL of 5 
mg/mL tetracycline was added.  The 200 mL culture was shaken 
overnight at 225 rpm and 37°C.  The next day, the culture was split 
into 5 roughly 40 mL lots in 50 mL polypropylene tubes.  Glycerol 
stocks were prepared from all but 1 tube by adding glycerol to 
approximately 15% in each tube.  That is about 7 mL of glycerol added 
to each tube and mixed thoroughly by pipeting up and down.  These 
glycerol stocks were stored at -80°C.  With an ample supply of 
pComb3XTT infected cells in storage, the remaining tube was used for 
a phagemid DNA preparation following the maxiprep (Qiagen) 
protocol.  The pComb3XTT phagemid preparation was used in PCR 
random mutagenesis [43]. 
 
The pComb3XTT clone encodes a human Fab antibody specific to 
tetanus toxoid, an approximately 150 kDa MW bacterial protein [43].  
The Fab fragment of an IgG (Figure 5a) possesses the light chain 
variable (VL) and constant (CL) domains.  It also possesses the heavy 
chain variable domain (VH) and constant domain 1 (CH1).  Since the 
goal was to get anti-amyloid antibodies, the heavy and light chain 
genes were mutagenized to generate a library of mutants.  PCR 
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primers were designed for amplifying the Fab DNA.  The sense primer, 
PC3SENSE, is just before VL and the reverse primer, PC3REVERSE, is 
just after CH1 (Figure 11, Table 2).  Error-prone PCR was used to 
generate mutated Fab DNA from the phagemid clone.  This technique 
involves the addition of manganese to the reaction.  This causes dNTP 
missubstitutions.  Several sets of conditions based on a published 
protocol [44] were tested before useable yields could be obtained. 
 
The following reaction mix provided the best yields: 100 pmol 
sense primer, 100 pmol reverse primer, 10 µL 10xPCR buffer 
(Promega), 28 µL MgCl2 (7 mM final from 25 mM stock), 0.2 mM dATP, 
0.2 mM dGTP, 1 mM dCTP, 1 mM dTTP, 0.25 mM MnCl2 (200 mM 
stock, autoclaved), 5 Units Taq (Promega), volume to 100 µL with 
nuclease-free water (Promega).  The following cycling conditions were 
used: 5 minute preheat at 95°C, 50 cycles of 15 seconds at 94°C, 30 
seconds at 45°C, and 90 seconds at 72°C.  Normally, 20 to 30 cycles 
are executed, but 50 cycles were used to increase yields.  The 5 










Table 2.  PCR primers.  PC3SENSE and PC3REVERSE were used for 
amplifying the Fab DNA, including both heavy and light chain 
sequences, from the pComb3X vector.  They were also used in the 
mutagenic PCR of this DNA sequence.  OMPSEQ and PELSEQ were 























 The mutagenic PCR products were gel purified via the PCR 
purification protocol (Qiagen).  Both the purified pComb3X phagemid 
vector and purified mutagenic PCR products were digested with the 
restriction endonuclease, SfiI (Roche).  Digestion was carried out by 
combining approximately 20 µg of the phagemid or 10 µg of the 
mutagenic PCR products with 360 Units of SfiI and 20 µL of 10x buffer 
M.  DNA concentrations were calculated by taking absorbance readings 
at 260 nm using a Molecular Devices Spectramax Plus spectrometer.  
For each sample, a blank reading was first taken by filling a quartz 
cuvette with deionized water.  The cuvette was emptied and the DNA 
sample was diluted 1:50 into deionized water and transferred into the 
same quartz cuvette to be read.  The concentration was calculated 
using equation 3.  The total amount of DNA in a given sample was 
calculated by multiplying this concentration by the total volume of the 
sample.  The digestion reaction volumes were adjusted to 200 µL with 
nuclease-free water and the reaction was incubated for 5 hours at 
50°C.  The mutagenic PCR products and the phagemid vector with the 
Fab insert cut out were gel purified using the spin miniprep protocol. 
DNA concentration = A260 * d * 50 µg/mL  Equation 3. 
A260 is the absorbance reading of the sample at 260 nm.  d is the 
dilution factor of the DNA sample into deionized water, 50 as 
described above.  50 µg/mL is a constant used to relate the 
absorbance at 260 nm to the amount of DNA in the sample. 
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The purified products were ligated with T4 DNA ligase (Roche) to 
generate a phagemid library.  Ligation was carried out by combining 
approximately 1.4 µg of cut pComb3X, 1.4 µg of cut mutagenic PCR 
products, 40 µL of 5x ligase buffer (Roche), and 10 µL of T4 DNA 
ligase.  The reaction volume was adjusted to 200 µL with nuclease-free 
water and the reaction was incubated overnight at room temperature.  
Successful ligation was verified by running the ligation reaction 
products on a 1% agarose gel alongside the cut products and the 
uncut phagemid.  This library was ethanol precipitated and washed for 
concentration, purification, and storage.  At a later stage in the work, 
6 clones were selected to be sent off for sequencing to verify 
successful mutagenesis.  The OMPSEQ primer was used for these 
sequencing reactions (Table 2).  The resulting electropherograms were 
examined for errors over 350 bases from each clone.  The number of 
mutations relative to the unmutated clone were counted and divided 
into the total number of bases counted to get the mutation rate.  
Roughly a 1.5% rate of base mutation was found.  Furthermore, 
BLAST searches on these sequences verified them to be human 
antibody κ light chain. 
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Amplification of Helper Phage 
Before undertaking the phage display experiments, helper phage 
needed to be prepared.  These must be ordered in a small amount and 
amplified significantly to provide enough for the phage display 
experiments.  VCSM13 helper phage (Stratagene), derived from the 
M13 K07 mutant, were ordered and amplified to an appropriate titer 
for use in the phage display experiments by using the protocol adapted 
from [42]. 
 
To being the procedure, 2 mL of SB medium was inoculated with 
2 µL of E. coli cells (XL1-Blue, Stratagene).  4 µL of 5 mg/mL 
tetracycline was added and the culture was shaken at 225 rpm for 1 
hour at 37°C.  Tetracycline selects for F+ male E. coli cells.  During the 
incubation, 3 dilutions of the ordered VCSM13 helper phage were 
made up in SB medium: 10-6, 10-7, and 10-8.  1 µL of each dilution was 
added to a separate 50 µL lot of this culture and incubated at room 
temperature for 15 minutes.  In the mean time, 3 LB+tetracycline 
agar plates were prewarmed to 37°C.  The 3 lots of infected cells were 
each diluted into 1 mL of SB medium and plated on a separate 
LB+tetracycline agar plate.  These plates were incubated overnight at 
37°C.  Sometimes the lowest dilution plate may have no colonies or 
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the highest dilution plate may have a lawn from which individual 
colonies cannot be picked.  This is the reason 3 phage dilutions are 
used.  It ensures there is at least one plate from which isolated 
VCSM13 phage plaques can be picked. 
 
The next day, 10 mL of prewarmed (37°C) SB medium was 
inoculated with 10 µL of XL1-Blue cells.  20 µL of 5 mg/mL tetracycline 
was added and the culture was shaken at 225 rpm for 1 hour at 37°C.  
A single VCSM13 plaque was transferred from one of the plates to the 
culture using a sterile pipet tip.  The culture was shaken at 225 rpm 
for 2 hours at 37°C.  It was transferred into to a 1 L Erlenmeyer flask 
with 240 mL of prewarmed (37°C) SB medium.  500 µL of 5 mg/mL 
tetracycline and 350 µL of 50 mg/mL kanamycin was added.  
Kanamycin selects for cells infected with VCSM13 phage since this 
phage genome imparts kanamycin resistance.  The 250 mL culture was 
shaken overnight at 225 rpm and 37°C. 
 
The next day, the culture was split into 6 50 mL polypropylene 
tubes and spun at 2,500g for 15 minutes using the Beckman Avanti J-
25I centrifuge and the JA-20 rotor.  The supernatants were transferred 
to fresh 50 mL tubes and incubated in a water bath at 70°C for 20 
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minutes.  They were spun again at 2,500g for 15 minutes in the same 
centrifuge and rotor.  The supernatants were transferred to fresh 50 
mL tubes and stored at 4°C until needed. 
 
 After the VCSM13 helper phage preparation was completed, the 
phage titer was determined.  The protocol adapted from [42] was used 
to check for a sufficient phage titer.  2 mL of SB medium was 
inoculated with 2 µL of XL1-Blue cells.  4 µL of 5 mg/mL tetracycline 
was added and the culture was shaken at 225 rpm for 1 hour at 37°C.  
During the incubation, 3 dilutions of the VCSM13 helper phage 
preparation were made up in SB medium: 10-7, 10-8, and 10-9.  1 µL of 
each phage dilution was added to a separate 50 µL lot of this culture 
and incubated at room temperature for 15 minutes.  The infected cells 
were diluted into 1 mL of SB medium and plated onto 3 separate 
LB+tetracycline agar plates.  These were incubated overnight at 37°C. 
 
 The next day, the number of plaques on each plate was counted.  
The 10-7 plate may have an uncountable lawn or the 10-9 plate may 
have few or no colonies.  At least 1 or 2 plates should have an 
adequate number of colonies to count.  The phage titer was 
determined by entering the count and the phage dilution factor for 
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each plate into equation 4.  The titer should be approximately 1012 to 
1013 (plaque-forming units/mL) pfu/mL.  The titer slowly decreases 
over time, but the VCSM13 phage preparation is stable for months at 
4°C. 
Phage input titer = (n * d * 50 µL) / 1 µL  Equation 4. 
n is the number of colonies counted on the plate.  d is the 
dilution factor of the phage preparation: 107, 108, or 109.  50 µL 
is the volume of the cell culture infected.  1 µL is the volume of 





The first round of phage selection, also called panning, began 
with library ligation and transformation.  The protocol for this process 
was adapted from [42].  To begin with, 1.4 µg of SfiI-cut pComb3X 
was combined with 650 ng of SfiI-cut mutagenic PCR product into a 
1.5 mL microcentrifuge tube.  10 µL of T4 DNA ligase (Invitrogen) and 
40 µL of 5x ligase buffer was added and the sample volume was 
adjusted to 200 µL with nuclease-free water.  This ligation reaction 
was incubated overnight at room temperature to allow for complete 
ligation.  Successful ligation was verified by running the ligation 
reaction products on a 1% agarose gel. 
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 The ligation products were precipitated by adding 1 µL of 
glycogen, 20 µL (0.1 volumes) of 3 M sodium acetate pH 5.2, and 440 
µL (2.2 volumes) of ethanol.  The reaction was mixed by inverting the 
tube several times.  The reaction was incubated overnight at 4°C.  The 
ligation products were spun down in a tabletop microcentrifuge 
(Eppendorf Centrifuge 5417R) at 20,000 rpm and 4°C for 15 minutes.  
The supernatant was discarded and the pellet was washed twice with 
70% ethanol.  The tube containing the pellet was drained, tapped dry 
onto a paper towel, and left to sit for 15 minutes in a fume hood to 
evaporate the remaining ethanol.  The dried pellet was dissolved in 30 
µL of nuclease-free water by heating to 37°C and vortexing to assist 
dissolution.  This is the ligated library sample.  It is imperative that 
this sample is well washed and well dried.  Remaining salt or ethanol 
could interfere with transformation. 
 
Before transformation, the ligated library sample and 2 
electroporation cuvettes were placed on ice for 10 minutes.  Just 
before transformation, a tube of 100 µL of XL1-Blue cells was thawed 
slowly on ice.  Though 2 transformations were ultimately done, only 
one tube of cells was thawed at a time.  This was done to prevent 
thawed cells sitting too long before transformation.  The longer they 
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sit, the lower the transformation efficiency.  Only after completely 
finishing the first transformation process, was the second tube of cells 
thawed. 
 
7 µL of the ligated library sample was added to the tube of 
thawed E. coli cells and mixed by pipeting up and down.  The 
remaining ligated library sample was stored at -80°C after completing 
both transformations.  The cells were incubated on ice for 1 minute 
after adding the library sample.  A 200 µL pipet tip with the end 
snipped off was used to transfer the cells to the electroporation 
cuvette.  The cuvette was transferred to the BIO-RAD Gene Pulser and 
electroporation was carried out at 2.5 kV, 25 µF, and 200 Ω.  A time 
constant of 4.0 to 4.5 is expected.  The cuvette was flushed 
immediately after electroporation with 1 mL followed by 2 flushes with 
2 mL of room temperature SOC medium.  These flushes were 
combined into a 50 mL polypropylene tube.  This culture was shaken 
at 225 rpm for 1 hour at 37°C. 
 
10 mL of SB medium, 3 µL of 100 mg/mL carbenicillin, and 30 
uL of 5 mg/mL tetracycline was added to the culture.  2 µL was 
removed from the culture and diluted into 200 µL of SB medium.  Onto 
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2 separate LB agar+carbenicillin plates, 10 µL and 100 µL of this 
1:100 dilution was plated and the plates were incubated overnight at 
37°C.  These plates were used for determining phage titer (Equation 
5).  The next day, the number of colonies on each plate was counted.  
The phage titer was determined by entering the counts, the plating 
volumes, 10 µL or 100 µL, and the culture volumes, 15 mL, into 
equation 5.  The 15 mL culture was shaken at 225 rpm for 1 hour at 
37°C.  4.5 µL of 100 mg/mL carbenicillin was added and the culture 
was shaken for another hour. 
Phage output titer = (n * 100 * Vc) / p  Equation 5. 
n is the number of colonies counted on the plate.  100 is the 
dilution factor of the infected culture: 200 µL / 2 µL.  Vc is the 
volume of the cell culture infected: 15 mL or 8 mL.  p is the 
plating volume: 0.01 mL or 0.1 mL.  The units are plaque-
forming units/mL or pfu/mL [42]. 
 
The culture was transferred to a 1 L Erlenmeyer flask and 2 mL 
of VCSM13 helper phage was added.  183 mL of prewarmed (37°C) SB 
medium, 92.5 µL of 100 mg/mL carbenicillin, and 370 µL of 5 mg/mL 
tetracycline were added.  The 200 mL culture was shaken at 225 rpm 
for 2 hours at 37°C.  280 µL of 50 mg/mL kanamycin was added and 
the culture was shaken overnight at 225 rpm and 37°C.  Kanamycin 
selects for helper phage infected cells.  This prevents the faster-
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growing uninfected cells from out-competing and overtaking the 
phage-producing infected cells. 
 
The 200 mL culture was transferred to a 500 mL polypropylene 
centrifuge bottle and spun at 3,000g for 15 minutes at 4°C using the 
Beckman Avanti J-25I centrifuge and the JLA-10.5 rotor.  The resulting 
supernatant was transferred to a clean 500 mL centrifuge bottle and 
32 mL of 25% PEG-8000 / 15% NaCl was added.  This was pipeted up 
and down to mix and kept on ice for 30 minutes.  During this waiting 
period, the cell pellet was resuspended in 1 mL of SB medium, 
transferred to a 2 mL microcentrifuge tube, and stored at -80°C.  The 
pellet can later be used in a phagemid DNA preparation.  The 
supernatant with 25% PEG-8000 / 15% NaCl added was spun at 
15,000g in the same centrifuge and rotor as earlier for 15 minutes at 
4°C.  The pellet is the phage pellet.  The supernatant was discarded 
and the bottle was drained by sitting it lip-down on paper towels for 10 
minutes.  The bottle was gently tapped to the paper towels to remove 
the last few drops and the lid was wiped dry. 
 
The phage pellet was thoroughly resuspended in 2 mL of 1% 
BSA in 1xPBS.  This suspension was transferred to a 2 mL 
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microcentrifuge tube and spun in a tabletop microcentrifuge at 20,000 
rpm and 4°C for 5 minutes.  The resulting clarified supernatant was 
transferred to a clean 2 mL microcentrifuge tube.  The pellet, 
consisting mainly of cell debris, was discarded.  Sodium azide was 
added to the preparation to 0.02% as a preservative so the 
supernatant could be stored at 4°C.  This preparation is the phage 
library, which was used immediately (the same day) for panning.  It 
can be stored and used at a later date, but it must be reamplified 
before panning.  This is necessary, because the activity of the 
presented Fab may drop over time in storage since it is not as rugged 
as the rest of the phage particle. 
 
Immediately after library ligation and transformation was 
completed, the first round of panning was started.  This process was 
employed for 3 rounds, though more rounds could be used if needed.  
The protocol was adapted from [42].  To begin with, 2 wells of a 96-
well high-binding polystyrene ELISA plate with flat-bottom wells 
(Corning/Costar) were coated with 200 ng of Aβ amyloid fibrils 
suspended in 50 µL of 1xPBS.  The plate was incubated overnight at 
37°C uncovered.  The coated wells were rinsed 2 times with ELISA 
wash buffer.  250 µL of 3% BSA was added to each well.  The plate 
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was covered with a plate sealer (Costar) and incubated for 1 hour at 
37°C.  During the incubation, a starter culture was prepared.  2 mL of 
SB medium and 4 µL of 5 mg/mL tetracycline was added to a 15 mL 
polypropylene tube and inoculated with 2 µL of XL1-Blue cells.  An 
identical culture was prepared and both were shaken at 225 rpm for 2 
to 2.5 hours at 37°C.  The OD of each should reach about 1.  This 
culture was used at a later stage in the protocol. 
 
The blocking solution was shaken out of the plate and 50 µL of 
the phage library preparation was added to both wells.  The plate was 
sealed and incubated for 1 hour at 37°C.  The phage solution was 
shaken out of the plate and both wells were washed 5 times each with 
ELISA wash buffer in the first round of panning.  In the second and 
third rounds of panning, they were washed 10 times each.  The 
thorough washing should remove most of the unbound phage from the 
wells.  The remaining wash buffer was shaken out and 50 µL of freshly 
prepared 10 mg/mL trypsin (Sigma) in 1xPBS was added to each well.  
There is a trypsin-sensitive flexible linker between the heavy chain and 
gp3 fragment in the pComb3X construct.  This allows trypsin to cleave 
bound phage particles from the plate, freeing them into solution [42].  
The plate was sealed and incubated for 30 minutes at 37°C.  The 
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contents of each well were pipeted up and down 10 times to 
thoroughly resuspend cleaved phage particles.  The contents of both 
wells were transferred to one of the 2 mL cultures prepared earlier.  
The infected culture was incubated at room temperature for 15 
minutes. 
 
6 mL of prewarmed (37°C) SB medium, 1.6 µL of 100 mg/mL 
carbenicillin, and 12 µL of 5 mg/mL tetracycline were added to a 50 
mL polypropylene tube.  The phage-infected 2 mL culture was 
transferred to this tube.  2 µL was taken from this culture and diluted 
into 200 µL of SB medium.  Onto 2 separate LB agar+carbenicillin 
plates, 10 µL and 100 µL of this 1:100 dilution was plated and 
incubated overnight at 37°C.  These plates were used for determining 
phage output titer (Equation 5).  The 8 mL culture was shaken at 225 
rpm for 1 hour at 37°C.  2.4 µL of 100 mg/mL carbenicillin was added 
and the culture was shaken for another hour.  In the mean time, 10-8 
and 10-9 dilutions of the phage preparation were prepared in 1% BSA 
in 1xPBS.  50 µL lots of XL1-Blue cells were infected with 1 µL of each 
phage dilution.  These were incubated at room temperature for 15 
minutes.  Onto 2 separate LB agar+carbenicillin plates, each lot of 
infected cells was plated.  These plates were used for determining 
 67
phage input titer (Equation 4).  All 4 plates, input and output titer, 
were incubated overnight at 37°C.  The next day, the number of 
colonies on each plate was counted.  The input titers were determined 
by entering the counts and phage dilution factors into equation 4.  The 
output titers were determined by entering the counts, the plating 
volumes, and the culture volumes, 8 mL, into equation 5. 
 
The 8 mL culture was transferred to a 1 L Erlenmeyer flask along 
with 2 mL of VCSM13 helper phage.  90 mL of prewarmed (37°C) SB 
medium, 46 µL of 100 mg/mL carbenicillin, and 184 µL of 5 mg/mL 
tetracycline was added.  The 100 mL culture was shaken at 225 rpm 
for 2 hours at 37°C.  140 µL of 50 mg/mL kanamycin was added and 
the culture was shaken overnight at 225 rpm and 37°C.  An ELISA 
plate was coated as described earlier and incubated overnight.  This 
plate is for use in the next round of panning, so it was not prepared 
during the final round of panning. 
 
The 100 mL culture was transferred to a 500 mL polypropylene 
centrifuge bottle and spun at 3,000g for 15 minutes at 4°C using the 
Beckman Avanti J-25I centrifuge and the JLA-10.5 rotor.  The 
supernatant was transferred to a clean 500 mL centrifuge bottle and 
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16 mL of 25% PEG-8000 / 15% NaCl was added.  This was pipeted up 
and down to mix and kept on ice for 30 minutes.  In the mean time, 
the cell pellet was resuspended in 1 mL of SB medium, transferred to a 
2 mL microcentrifuge tube, and stored at -80°C.  Also, the ELISA plate 
wells coated overnight were washed and blocked as described earlier.  
The supernatant with 25% PEG-8000 / 15% NaCl added was spun at 
15,000g in the same centrifuge and rotor for 15 minutes at 4°C.  The 
pellet is the phage pellet.  The supernatant was discarded and the 
bottle was drained by sitting it lip-down on paper towels for 10 
minutes.  The bottle was gently tapped to the paper towels to remove 
the last few drops and the lid was wiped dry. 
 
The phage pellet was thoroughly resuspended in 2 mL of 1% 
BSA in 1xPBS.  This suspension was transferred to a 2 mL 
microcentrifuge tube and spun in a tabletop microcentrifuge at 20,000 
rpm and 4°C for 5 minutes.  The resulting clarified supernatant was 
transferred to a clean 2 mL microcentrifuge tube.  The pellet, 
consisting mainly of cell debris, was discarded.  Sodium azide was 
added to the preparation to 0.02% as a preservative so the 
supernatant could be stored at 4°C.  This preparation is the phage 
library, which was used immediately for the next round of panning.  
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That is, the protocol was started over from the beginning right away, 
except on the last round of panning. 
 
Phage ELISA 
 During the panning process, the progression was monitored to 
ensure that the library was being enriched in amyloid-binding phage.  
Phage ELISA experiments were run on the phage libraries at each step 
to test the affinity of the library at a given stage for amyloid.  The 
phage ELISA protocol shares some similarities to the ELISA protocol 
already described except for a few key differences.  In place of a 
primary antibody, a phage library was used.  For a secondary 
antibody, an anti-M13 phage antibody was used.  Therefore, this 
protocol tests the ability of the library as a whole to bind amyloid 
fibrils.  It was also used to test individual clones. 
 
For each phage ELISA, columns 1 and 2 of a 96-well high-
binding polystyrene ELISA plate with flat-bottom wells were coated 
with 200 ng of Aβ amyloid fibrils suspended in 50 µL of 1xPBS.  The 
plate was incubated overnight at 37°C uncovered.  The next day, the 
plate was washed 2 times with ELISA wash buffer.  To block the plate, 
each well was filled with 250 µL of ELISA blocking solution.  The plate 
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was covered with a plate sealer and incubated at 37°C for 1 hour.  100 
µL of ELISA blocking solution was pipeted into each well of columns 1 
and 2.  100 µL of the fresh phage preparation was transferred into well 
A1, making 200 µL in total in the well,  and pipeted up and down 4 
times to mix (Figure 9).  This process was continued down column 1, 
from well H1 to well A2, and down thru well F2.  The plate was 
covered with a plate sealer and incubated at 37°C for 1 hour.  The last 
2 wells are for taking background readings since they contain no 
phage. 
 
The plates were washed 2 times with ELISA wash buffer.  A 
1:5000 dilution of the secondary antibody, biotinylated anti-M13 phage 
(Exalpha), was prepared in ELISA blocking solution.  100 µL of this 
preparation was pipeted into each well.  The plate was covered with a 
plate sealer and incubated at 37°C for 40 minutes.  The plate was 
washed 2 times with ELISA wash buffer.  A 1:1000 dilution of Delfia 
Europium-labeling streptavidin (Perkin Elmer) was prepared in ELISA 
blocking solution.  100 µL was pipeted into each well.  The plate was 
covered with a plate sealer and incubated at room temperature in the 
dark for 1 hour.  The plate was washed 3 times with ELISA wash 
buffer.  100 µL of Delfia enhancement solution (Perkin Elmer) was 
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pipeted into each well and a Wallac Victor2 1420 Multilabel Counter 
was used for detection.  The binding data were analyzed much the 
same as in the other ELISA experiments.  However, no concentration 
values were available.  Binding results were plotted against log(dilution 
factor of phage) and the curves were examined qualitatively.  No 
calculations were done based on these data. 
 
 After the panning process was completed and the library was 
enriched in fibril-binding phage, clones were selected for further 
analysis.  The protocol for picking clones begins with preparing a 
starter culture.  2 mL of SB medium and 4 µL of 5 mg/mL tetracycline 
were added to a 15 mL polypropylene tube and inoculated with 2 µL of 
XL1-Blue cells.  An identical culture was prepared for each round of 
panning conducted and for the nonpanned library (4 cultures total for 
3 rounds of panning and the nonpanned library).  These cultures were 
shaken at 225 rpm for 2 to 2.5 hours at 37°C.  The OD of each should 
reach about 1.  50 µL of each phage preparation, one from each round 
of panning, was added to a separate culture and incubated at room 
temperature for 15 minutes.  Onto LB agar+carbenicillin plates, 10 µL 
of each culture was plated.  These plates were incubated overnight at 
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37°C.  Less or more culture may be plated if 10 µL results in too many 
or too few colonies. 
 
The next day, 2 mL of SB medium, 4 µL of 5 mg/mL tetracycline, 
and 1 µL of 100 mg/mL carbenicillin were added to several 15 mL 
polypropylene tubes.  Enough tubes were prepared for the desired 
number of clones.  Isolated colonies were picked from each plate with 
sterile pipet tips and cultures were inoculated with a single clone into 
each tube.  8 clones were picked on the first run of this protocol and 
16 on the next.  The cultures were shaken at 225 rpm for 2 to 2.5 
hours at 37°C.  The plates were stored by sealing with parafilm and 
keeping at 4°C.  6 mL of prewarmed (37°C) SB medium, 3 µL of 100 
mg/mL carbenicillin, and 12 µL of 5 mg/mL tetracycline was added to 
a 50 mL polypropylene tube for each clone.  The phage-infected 2 mL 
cultures were added to these tubes.  The 8 mL cultures were shaken 
overnight at 225 rpm and 37°C.  The following day, glycerol stocks 
were prepared from these cultures by adding glycerol to approximately 
15% in each culture tube.  That is about 1 to 1.2 mL of glycerol per 
tube.  These glycerol stocks were mixed thoroughly by pipeting up and 
down and stored at -80°C. 
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 After selecting clones, the affinity of each was tested to 
determine if it possessed the desired binding properties.  This entailed 
producing small-scale phage preparations of the clones and testing 
their binding properties by phage ELISA.  The protocol for small scale 
phage preparations was adapted from [42].  For each clone to be 
tested, 10 mL of SB medium, 20 µL of 5 mg/mL tetracycline, and 5 µL 
of 100 mg/mL carbenicillin was added to several 50 mL polypropylene 
tubes.  Each was inoculated with a glycerol stock scraping from a 
different clone.  The cultures were shaken at 225 rpm for 6 hours at 
37°C.  100 µL of VCSM13 helper phage was added to each culture.  
The cultures were shaken for an additional 2 hours at 225 rpm and 
37°C.  14 µL of 50 mg/mL kanamycin was added to each culture and 
the cultures were shaken overnight at 225 rpm and 37°C. 
 
The next day, 1.2 mL of each supernatant was transferred into a 
fresh 2 mL microcentrifuge tube.  These tubes were spun at 3,500 rpm 
in a tabletop microcentrifuge for 15 minutes.  The supernatants were 
transferred to fresh 2 mL microcentrifuge tubes and the cell pellets 
were frozen since they can later be used in phagemid preparations.  To 
the 1.2 mL supernatants, 300 µL of 25% PEG-8000 / 15% NaCl was 
added.  The supernatants with 25% PEG-8000 / 15% NaCl added were 
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mixed by inverting the tubes several times.  They were incubated on 
ice for 30 minutes.  The tubes were spun at 20,000 rpm and 4°C for 
15 minutes.  For each tube, the supernatant was drawn out with a 
pipet, taking care not to disturb the pellet.  All tubes were spun 20 
seconds longer and the remaining supernatant was drawn out.  Each 
tube was carefully tapped upside down on a paper towel to remove the 
last of the PEG.  All the tubes were allowed to dry for 10 minutes in a 
fume hood.  Each phage pellet was resuspended in 100 µL of 1% BSA 
in 1xPBS.  These clonal phage preparations were used right away in 
phage ELISAs as previously described.  The only difference was that 
100 µL of a clonal phage preparation was used in place of 100 µL of a 
phage library preparation.  The binding curves were plotted and 
examined in the same manner as the phage library ELISA 
experiments. 
 
Production of Soluble Fab 
Soluble Fab production was explored in selected clones as well 
as the original unmutated clone.  Each phagemid clone was isolated 
and transformed into E.coli cells of a nonsuppressor strain.  Cultures 
were grown up and induced to produce soluble Fab protein and whole 
cell extracts from these cultures were tested for the presence of Fab 
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protein.  After growing up induced cultures, an acetone extraction 
protocol (Dr. Ronald Wetzel) was used to remove lipids and get a total 
protein extract.  Western blots of the protein extracts were run. 
 
For each clone, a cell pellet prepared earlier was used in a 
plasmid preparation to isolate and purify the phagemid DNA.  Pellets 
saved from the clonal phage ELISA experiments were used.  These 
were subjected to the spin miniprep protocol (Qiagen).  
Electrocompetent E. coli cells of a nonsuppressor strain (TOP10, 
Invitrogen) were transformed with each phagemid clone following the 
protocol already described under the heading “PCR Random 
Mutagenesis”.  The only difference was the use of the TOP10 strain of 
E. coli in place of the XL1-Blue strain.  After electroporation, 10 mL of 
SB medium, 3 µL of 100 mg/mL carbenicillin, and 30 uL of 5 mg/mL 
tetracycline was added to the 5 mL of SOC medium flushes.  The 15 
mL culture was shaken at 225 rpm for 1 hour at 37°C.  4.5 µL of 100 
mg/mL carbenicillin was added and the culture was shaken overnight 
at 225 rpm and 37°C.  The next day, glycerol stocks were prepared 
from the cultures by adding glycerol to approximately 15% in each 
tube and mixing thoroughly by pipeting up and down.  These glycerol 
stocks were stored at -80°C.  The remaining material from the plasmid 
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preparation of each clone was sent off for sequencing.  Including the 
unmutated clone, five clones were sequenced in total.  The PELSEQ 
and OMPSEQ primers were used for these sequencing reactions (Table 
2).  BLAST searches on the resulting sequences verified them to be 
human antibody heavy chain Fd fragment and κ light chain, 
respectively. 
 
For testing soluble Fab production, fresh cultures were prepared 
using the glycerol stocks as inoculants.  For each clone, 5 mL of SB 
medium, and 2.5 µL of 100 mg/mL carbenicillin were added to several 
50 mL polypropylene tubes.  Since the heavy and light chain genes are 
under the lacZ promoter in the pComb3X vector, IPTG can induce their 
expression.  Each tube was inoculated with a glycerol stock scraping 
from a different TOP10 culture clone.  The cultures were shaken for 6 
hours at 225 rpm and 37°C.  50 µL of 0.1 M IPTG was added to each 
culture and the cultures were shaken overnight at 225 rpm and 37°C. 
 
The following day, 1 mL of each culture was transferred to a 2 
mL microcentrifuge tube.  The tubes were spun at 5,000 rpm in a 
tabletop microcentrifuge for 5 minutes.  The supernatants were 
discarded and the cell pellets were frozen at -80°C.  The pellets were 
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thawed and each was resuspended in 80 µL of cell suspension buffer.  
8 µL of 20% SDS and 8 µL of 1M βME was added.  Each cell 
suspension was pipeted up and down and vortexed vigorously to mix.  
They were heated to 90°C for 2 minutes and then cooled.  1 mL of 
acetone was added to each tube and mixed by vortexing.  The tubes 
were incubated on ice for 10 minutes.  They were spun at 5,000 rpm 
in a tabletop microcentrifuge for 1 minute.  The supernatants were 
discarded and the pellets were left in a fume hood for 15 minutes to 
dry.  The pellets were resuspended in 300 µL of [7.5 parts 1xPBS, 2.25 
parts NuPage 4x loading dye (Invitrogen), 0.25 parts 1M βME] by 
pipeting up and down and vortexing vigorously.  They were heated to 
90°C for 2 minutes and then cooled.  The tubes were spun at 5,000 
rpm in a tabletop microcentrifuge for 1 minute.  A protease inhibitor, 
Fluka Pefabloc SC (Fisher), was added to 1mM final concentration to 
prevent protein degradation.  25 µL of each sample was loaded into a 
NuPage polyacrylamide gel lane (Invitrogen) for analysis.  The SeeBlue 
Plus 2 MW standard (Invitrogen) was loaded into one lane of the gel.  
The gel was run through a SDS-PAGE experiment at 150 V for 70 
minutes using a BIO-RAD PowerPac 200  following the NuPage protocol 
(Invitrogen).  1x MOPS SDS running buffer (Invitrogen) was used in 
the run with NuPage antioxidant (Invitrogen) added.  Gels prepared in 
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this fashion were used in western blot experiments to determine if 
there is any Fab protein present. 
 
 For each western blot, a western transfer was run onto a PVDF 
membrane (BIO-RAD).  The NuPage protocol (Invitrogen) was followed 
for the transfer.  After the transfer, the PVDF membrane was used in a 
western blot.  The membrane was blocked by incubating in a 5% BSA 
solution for 1 hour.  The membrane was washed 3 times with ELISA 
wash buffer by shaking the membrane in the buffer for 5 minutes each 
wash.  The membrane was incubated in a 1:2500 dilution of the 
primary antibody in ELISA blocking solution for 1 hour.  For blots 
against the HA tag of the fusion protein, a monoclonal anti-HA biotin 
conjugate antibody (Sigma) was used.  In another replicate of the 
same experiment, a monoclonal anti-HA HRP conjugate antibody 
(Roche) was used.  For blots against the antibody chains, a polyclonal 
goat anti-human IgG, heavy and light chain, HRP conjugate (Pierce) 
was used.  Since the gel running conditions were reducing, it was 
necessary to use chain-specific antibodies rather than anti-Fab 
antibodies.  A polyclonal mixture was used in case some of the 
antibody mutant clones have mutations in the epitope recognized by a 
particular monoclonal antibody.  In this experiment, a purified human 
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IgG was run on the same gel as the positive control.  After the primary 
antibody incubation, the membrane was washed 3 times as before.  
When the primary antibody was a biotin conjugate, ExtrAvidin 
Peroxidase (Sigma) was used as a secondary diluted to 1:5000 in 
ELISA blocking solution.  The membrane was incubated in this solution 
for 1 hour.  It was washed 3 times as before.  After a membrane was 
labeled with an HRP conjugate, it was treated with a peroxidase 
substrate to stain the labeled bands.  A CN/DAB substrate (Pierce) was 
used following the provided protocol.  The membrane was incubated in 
this substrate and monitored until bands developed. 
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Chapter III 
Antibody Binding Results and Discussion 
 
 
Several experiments were conducted using the anti-amyloid 
antibodies available in our lab.  Among these were experiments 
studying the binding characteristics of these antibodies to Aβ amyloid 
fibrils.  These included salt and pH effect experiments to examine anti-
amyloid antibody binding properties.  These also included binding 
studies using fragments of these IgM antibodies to determine the 
importance of avidity effects to binding.  The majority of the work 
focused primarily on exploring anti-amyloid antibody binding to 
different amyloid fibrils, specifically fibrils of proline and alanine 
mutants of Aβ.  These experiments sought to explore the impact of 
single-residue changes and potential fibril structural differences on 
antibody binding. 
 
Salt and pH Effects on WO1 Binding to Aβ Fibrils 
 This set of experiments was designed to gain some insight into 
the nature of WO1 binding to Aβ amyloid.  They ask the question of 
whether electrostatic or hydrophobic interactions are predominant in 
WO1 binding.  Electrostatic interactions are sensitive to changes in 
buffer ionic strength and pH conditions, whereas hydrophobic 
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interactions are not significantly impacted.  This is important as a 
reliance on electrostatic interactions supports a specific mode of 
binding.  A dependence on hydrophobic interactions, on the other 
hand, more likely suggests nonspecific binding.  Binding of the WO1 
antibody to Aβ fibrils was tested under various salt and pH conditions 
(Table 1).  All solutions used in the salt effect experiments were 
buffered with 5 mM HEPES.  Due to the low ionic strength of this buffer 
compound, it should not greatly impact the overall ionic strength of 
the buffer.  In addition, these solutions were buffered to pH 7.5, near 
physiological pH conditions.  All solutions used in the pH effect 
experiments contained 150 mM NaCl to provide approximate 
physiological ionic strength conditions. 
 
Four different salts were tested at comparable ionic strengths to 
determine if the particular salt present in the buffer has a significant 
impact on antibody binding.  The four chosen were 1xPBS, NaCl, KCl, 
and NaPO4 (Table 1).  1xPBS is the standard buffer used in the binding 
experiments.  The other three salts were chosen to compare two 
different anions and cations.  The affinity varied from about 2 nM in 
1xPBS to about 10 nM in 75 mM NaPO4, less than an order of 































Figure 12.  Salt effect on WO1 binding.  Binding under various salt 
conditions was calculated from sigmoid midpoints: 5 mM HEPES only 
was 4 nM, 150 mM NaCl was 4 nM, 150 mM KCl was 8 nM, 75 mM 
NaPO4 was 10 nM, 600 mM NaCl was 20 nM, and 1xPBS was 2 nM. 
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there was some variation, binding was relatively comparable in the 
presence of the different salts. 
 
Binding was tested under three different ionic strength 
conditions: 0 mM NaCl, 150 mM NaCl, and 600 mM NaCl (Table 1).  
Binding was strongest in the near physiological ionic strength buffer, 
150 mM NaCl, at an affinity of 4 nM (Figure 12).  In a low ionic 
strength buffer, 5 mM HEPES only, binding is similar.  In a high ionic 
strength buffer, 600 mM NaCl, binding dropped sharply.  This 
manifested in a reduction of both the magnitude and the affinity of 
binding.  The significantly reduced binding in high salt suggests that 
electrostatic interactions are relatively important to binding and 
hydrophobic interactions are relatively unimportant.  That is not to say 
that binding is solely controlled by electrostatic interactions, but it 
does suggest that they are relatively important to binding. 
 
WO1 binding was tested in a range of pH conditions (Table 1).  
The data produced a continuum of binding affinities with the strongest 
binding at near physiological conditions, pH 7.4 (Figures 13a & b).  
There was, however, a discontinuity at pH 5.8 between the PIPES and 
citrate buffers (Figure 13b).  We are not sure exactly why this  
 










































citrate pH 3.0 to 5.8
PIPES pH 5.8 to 7.4
Bicine pH 7.4 to 8.5
CHES pH 8.5 to 10.0
B
 
Figure 13.  pH effect on WO1 binding.  The curves in graph A show 
binding under various pH conditions.  Binding affinities were calculated 
from the sigmoid midpoints: citrate pH 3.0 showed essentially no 
binding, pH 5.8 was 2 nM, PIPES pH 5.8 was more than 20 nM, pH 7.4 
was 2 nM, Bicine pH 7.4 was 1.5 nM, pH 8.5 was 16 nM, CHES pH 8.5 
was 10 nM, pH 10.0 was very low binding (could not be calculated, but 
no better than 50 nM).  Graph B is a plot of -log(affinity) across the pH 
range of 3.0 to 10.0.  Affinities for the pH 3.0 and 10.0 data points 
could not be calculated since they were so low.  The value 6 was 
substituted for each of these. 
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inconsistency appeared, but it may be due to buffer effects besides the 
pH.  Even with the gap present, a clear trend arose with binding 
dropping off sharply at higher and lower pH conditions.  This indicated 
that WO1 is pH-optimized for Aβ amyloid binding.  If hydrophobic 
interactions were predominant in binding, this would likely not be the 
case.  This reinforces the salt effect results suggesting that binding 
depends at least in part on electrostatic interactions. 
 
Binding of rIgM WO2 Fragments to Aβ Fibrils 
This study was conducted to determine if antibody fragments of 
lower valency than IgM can still bind Aβ fibrils.  Since IgM molecules 
possess ten antigen binding domains (Figure 5), there is likely some 
avidity effect involved in their binding to amyloid fibrils.  That is, 
several binding domains contribute to the binding affinity in a 
cooperative manner.  This study explores the importance of that effect 
in the binding of the WO2 IgM molecule to Aβ amyloid.  WO2 
possesses very similar binding properties to WO1. 
 
The fragment generated was rIgM, a monovalent fragment of the 
IgM molecule.  The advantage of working with this particular fragment 
is that the same secondary antibody, biotinylated goat anti-mouse IgM 
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(µ-chain specific), can be used as with the whole IgM molecules in 
ELISA experiments.  The same binding and concentration 
determination experiments were run on these fragments as on the 
whole IgM antibodies.  The only difference was in calculating 
concentrations.  The molecular weight of the fragment was treated as 
approximately 90 kDa instead of 900 kDa, so the effective 
concentration was increased by a factor of ten. 
 
WO2 rIgM binds less strongly to Aβ fibrils than WO2 IgM, 
possibly due to the reduction in valency (Figure 14a).  However, 
control rIgM generated from mouse IgM (Calbiochem) binds more 
strongly than control IgM (Figure 14b).  In fact, it binds with similar 
affinity to WO2 rIgM.  This is a surprising result.  Perhaps exposure of 
constant regions enhances nonspecific binding of the rIgM fragment.  
Due to the weaker binding of WO2 rIgM and the stronger binding of 
control rIgM, WO2 fragments do not bind significantly more strongly 
than control IgM fragments.  Avidity effects appear to be important in 













































Figure 14.  Binding of WO2 rIgM fragments to Aβ fibrils.  Graph 
A shows that the WO2 rIgM fragment bound much less strongly than 
the WO2 IgM: 32 nM versus 2.5 nM.  Graph B shows that the control 
rIgM fragment bound more strongly than the control IgM: 25 nM 
versus 130 nM.  The fragments ultimately bound with very similar 




PGA1 Binding to Aβ Amyloid versus Polyglutamine Aggregates 
 Among the battery of antibodies available in our lab are several 
raised against polyglutamine aggregates.  In characterizing these, we 
found one to be of particular interest because of its ability to bind Aβ 
amyloid more strongly than polyglutamine aggregates.  This antibody, 
PGA1, bound Aβ aggregates much more strongly than it did 
polyglutamine aggregates.  PGA1 is a monoclonal IgM isolated from 
mouse myeloma cultures (Dr. Brian O’Nuallain, unpublished data).  It 
was generated from a mouse immunized with amyloid-like 
polyglutamine aggregates [45].  Approximate PGA1 affinities were: 20 
nM to Aβ fibrils, 70 nM to Q30 aggregates, and 70 nM to Q50 
aggregates.  PGA1 bound to Aβ fibrils at least three times better than 
to either polyglutamine aggregate tested (Figure 15).  In addition, the 
magnitude of the binding affinity at saturation was significantly higher 
for Aβ fibrils.  These are surprising results considering that PGA1 was 
raised against polyglutamine aggregates.  The antibody bound 
aggregates of entirely different protein constituents more strongly 
than the immunogenic aggregates.  This highlights the amyloid 
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Figure 15.  PGA1 binding to Aβ fibrils versus polyglutamine 
aggregates.  Approximate PGA1 affinities: to Aβ fibrils was 20 nM, to 




WO1 and PGA1 Binding to Fibrils of Aβ Proline Mutants 
Learning the effects of mutating different residues could tell 
more about where and how the anti-amyloid antibodies bind to Aβ 
fibrils.  Towards this end, WO1 and PGA1 binding to a number of fibrils 
of Aβ mutants was analyzed.  The first set tested was made up of 
proline mutant Aβ fibrils.  These were the products of a proline 
scanning mutagenesis project [34].  Fibrils of these mutants were 
provided by Angela Williams.  Though prolines are known to destabilize 
β-sheet structure, a defining characteristic of amyloids, fibrils 
managed to grow for all the proline mutants tested.  However, the 
mutant fibrils may be structurally different from wild-type as reflected 
in varied fibril stabilities and HD exchange protection [34].  EMs of 
these fibrils were obtained and thioflavin T (ThT) binding was 
measured to show that the samples are indeed fibrils and not 
amorphous aggregates [34].  In addition, HD exchange studies 
suggest that the proline mutant fibrils are structurally similar to wild-
type Aβ fibrils [34].  Of course, the fibrils are probably not structurally 
identical to wild-type.  The purpose of these experiments was to 
determine if the proline mutant Aβ fibrils are still recognized as 
amyloid by the anti-amyloid antibodies.  These experiments also 
explored differences in binding to each proline mutant fibril. 
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 WO1 binding to a number of proline mutant fibrils of Aβ was 
tested.  Binding was tested in triplicate where possible.  Due to the 
lack of involvement of the amino terminus (~15 residues) in fibril 
structure [31-33], many mutants from that region were not tested.  
Only a representative few mutants from the amino terminus were 
selected.  Mutants at residues 18, 19, 20, and 31 were also not tested.  
These fibrils were not available at the time of this experiment.  A 
double proline mutant (23, 30) and a quadruple proline mutant (9, 23, 
30, 37) were tested.  These both possess proline mutations in each of 
the turn regions in the model (Figure 4).  The quadruple mutant 
possesses two additional mutations, one N-terminal and the other C-
terminal of the amyloid core in the model.  The affinity of WO1 for 
most of the mutant fibrils was comparable to that for wild-type Aβ 
fibrils (Figures 16 & 17).  In figure 16, the affinity is represented as a 
function of the free energy difference approximation (∆∆Gapp) between 
WO1 binding to wild-type fibrils and proline mutant fibrils.  These 
calculations are not entirely legitimate since the binding curve 
midpoints on which they are based do not represent true dissociation 
constant (Kd) values.  However, they are useful approximations for 




















Figure 16.  Summary of WO1 binding to proline mutants of Aβ.  
The six sets of sigmoid curves on the following pages show the binding 
affinity obtained for WO1 binding to fibrils of each mutant.  These 
represent one set of data, but it was obtained in triplicate with a few 
exceptions: single replicates for D23P and I32P, duplicates for F4P, 
N27P, G29P, 2P and 4P, and 5 replicates for K16P.  2P and 4P are the 
double (23, 30) and quadruple (9, 23, 30, 37) proline mutants, 
respectively.  From the curves, the binding affinity of WO1 for each 
mutant fibril was calculated.  The free energy difference approximation 
(∆∆Gapp) for WO1 binding to each mutant relative to WT fibrils was 
calculated using the equation: ∆∆Gapp = R*T*ln(WT affinity / mutant 
affinity).  R = 1.987 kcal/(°K * mol) and T = 310.14 °K.  These values 
were plotted on the bar graph with the error bars showing the 
standard deviation between replicates.  In this figure, a higher, 
positive ∆∆Gapp indicates that WO1 binds more strongly to the 



















































Figure 17.  WO1 binding to proline mutants of Aβ.  These graphs 
show one set of ELISA binding data for WO1 binding to proline 
mutants of Aβ.  Kaleidagraph was used to calculate the affinity of WO1 
for each mutant by obtaining a sigmoid fit of each curve and extracting 
the midpoint.  For those curves that did not reach an obvious plateau, 
the highest data point was duplicated at x = 6 to approximate a 




































































































Figure 17.  Continued. 
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the mutant fibrils, but the affinity for several was significantly higher 
than that for wild-type fibrils.  In many cases, such as the mutants at 
residues 4, 6, 9, and 14, the difference was relatively small with 
∆∆Gapp values less than about 0.5 kcal/mol.  Several mutant fibrils, 
such as those at residues 12, 15, 33, and 37, showed significantly 
better binding with ∆∆Gapp values around 0.7 to 1 kcal/mol.  One 
mutant stood up above all the rest.  The K16P mutant fibrils were 
bound much more strongly with a ∆∆Gapp value around 1.8 kcal/mol.  
This amounts to about twenty times stronger binding compared to 
wild-type fibrils.  The peak representing this mutant stands out 
prominently in figure 16. 
 
 Since WO1 managed to bind most of the proline mutant fibrils 
comparably or better to wild-type (Figures 16 & 17), it appears that 
the structural differences between the different mutant fibrils did not 
remove the amyloid characteristics of the fibrils as seen by WO1.  Of 
particular note, WO1 bound the K16P mutant fibrils of Aβ much more 
strongly than wild-type.  In our model of Aβ protofilament structure, 
residue 16 lies towards the end of a β-sheet (Figure 18a).  It is near 
the interface between the unstructured amino-terminus and the 






Figure 18.  Aβ protofilament cross-section: WO1 and PGA1 
binding to mutant fibrils.  Based on the binding data, the most 
significant residues are highlighted in yellow and pointed out with 
arrows.  This figure considers proline (P), alanine (A), cysteine (C), 
and carboxymethylthio-modified cysteine (CMTC) mutant data.  There 
are other residues with significant binding enhancement in some 
cases, but only the most significant are shown here.  Note that 
residues 16 and 36 each lie between the amyloid core and the amino- 
or carboxy-terminus, respectively.  Also note that residues 27, 28, 30, 











affinity for K16P over all the other single proline mutant fibrils and 
wild-type Aβ suggests that this residue is at an important junction to 
WO1 binding.  There are many possible explanations for why this may 
be the case.  One possible explanation is that the rigid proline, while 
destabilizing fibril structure globally, may serve to solidify a structural 
epitope recognized by WO1.  Another explanation is that the 
destabilization may simply make the antibody epitope more accessible 
to WO1.  The second explanation could involve “frayed” fibril ends.  As 
was earlier mentioned, fibrils are composed of multiple protofilaments 
wound about one another [23].  It could be the case that fibril 
destabilization could weaken the association of these protofilaments at 
the fibril ends.  These frayed ends could make the WO1 binding site 
more accessible.  This will be discussed in more detail later. 
 
WO1 binding to double and quadruple proline mutant fibrils was 
also tested [31-33].  These results are shown in figures 16 and 17f.  
WO1 binding to the double proline (residues 23 and 30) mutant fibrils 
was similar to wild-type.  WO1 binding to the quadruple proline 
(residues 9, 23, 30, and 37) mutant fibrils was surprisingly good.  With 
four prolines in the sequence, one would have predicted that fibrils 
would not grow or would be very unstable.  Given that the fibrils did 
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grow, one might expect a greatly altered fibril structure.  However, the 
binding data suggests that the fibrils maintained amyloid character as 
seen by WO1.  The enhanced affinity of WO1 for these fibrils may be 
primarily due to the proline at residue 37 since the single proline 
mutants at the other three residues (9, 23, and 30) all seem to have 
little impact on binding (Figure 16).  In building our model of the 
amyloid structure, we have interpreted this result to indicate that 
positions 9 and 37 are N-terminal and C-terminal, respectively, to the 
β-sheet portion of the amyloid, and positions 23 and 30 are in turn 
regions between β-sheet elements (Figure 18).  Prolines are more 
likely to be tolerated in turn and disordered segments, and at these 
positions might thus not be destabilizing to fibril structure. 
 
Since PGA1 possesses strong binding to Aβ amyloid (Figure 15), 
its binding was also tested against the array of available proline 
mutant Aβ fibrils.  PGA1 binding was tested in duplicate.  Just as with 
WO1, the goal was to see the effects of proline mutations on antibody 
binding.  Furthermore, this allowed for a comparison of the binding 
profiles of WO1 and PGA1 to the proline mutant fibrils.  For the most 
part, the PGA1 binding profile resembles that of WO1 except for a few 
major differences (Figure 19).  The enhanced binding for K16P, at 
 
 
















Figure 19.  Summary of PGA1 binding to proline mutants of Aβ.  
Data is in duplicate except: 4 replicates for V36P and a single replicate 
for G25P.  From the binding curves (not shown), the binding affinity of 
PGA1 for each mutant fibril was calculated.  The free energy difference 
approximation (∆∆Gapp) for PGA1 binding to each mutant relative to WT 
fibrils was calculated using the equation shown in figure 16.  These 
values were plotted on the bar graph with the error bars showing the 
standard deviation between replicates.  In this figure, a higher, 
positive ∆∆Gapp indicates that PGA1 binds more strongly to the 




about 0.8 kcal/mol, is not nearly as pronounced as was found for 
WO1.  There is an island of enhanced binding from mutants I32P to 
V36P.  PGA1 binding to V36P was particularly good with a ∆∆Gapp value 
around 3.7 kcal/mol.  This amounts to about one hundred times 
stronger binding compared to wild-type fibrils.  This suggests that 
residue 36 has a strong influence on the PGA1 binding site, not unlike 
the relationship between residue 16 and WO1 binding.  In our model, 
residue 36 lies towards the end of a β-sheet near the interface 
between the unstructured carboxy-terminus and the amyloidogenic 
core of the Aβ peptide (Figure 18b).  It is within a region of the 
peptide reminiscent of the locale of residue 16.  Therefore, the 
enhanced binding of PGA1 may be due to similar effects as were 
discussed for WO1 binding.  This suggests that the PGA1 and WO1 
binding sites may be related.  However, the marked differences in 
binding to the proline mutants K16P and V36P emphasizes that the 
binding sites are not identical.  The other clear difference is the greater 
magnitude of binding enhancement to the mutants in the range of 
residues 32 to 37 (Figures 16 & 19).  Though both WO1 and PGA1 bind 
to Aβ fibrils, the different binding patterns they exhibit to proline 
mutants suggests they do not target the exact same binding site. 
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WO1 and PGA1 Binding to Fibrils of Aβ Alanine Mutants 
A project currently in progress involves alanine scanning 
mutagenesis of the Aβ peptide sequence.  Fibrils of these mutants are 
grown up and analyzed with the same techniques used for the proline 
mutants (Angela Williams, unpublished data).  Alanine mutants should 
not have drastically altered fibril structures when compared to proline 
mutants.  This means the resulting binding data should be more 
informative as to local effects of different residues on antibody binding.  
Not all of the alanine mutant fibrils were assayed since not all were 
available at the time of testing. 
 
Binding was tested in duplicate for all available mutant fibrils.  
Like the proline mutant results, WO1 binding to most of the alanine 
mutant fibrils was comparable to wild-type.  There were, nonetheless, 
a few exceptions (Figure 20).  The N27A mutant fibrils were bound 
much more strongly with a ∆∆Gapp value around 2.1 kcal/mol.  This 
amounts to about thirty times stronger binding compared to wild-type 
fibrils.  In the model, this residue lies within a β-sheet (Figure 18a).  
Asparagine is a polar amino acid, but it carries no formal charge under 
physiological pH conditions.  The drastically improved binding to this 






















Figure 20.  Summary of WO1 binding to alanine mutants of Aβ.  
Data is in duplicate except: 3 replicates for K16A and L34A.  From the 
binding curves (not shown), the binding affinity of WO1 for each 
mutant fibril was calculated.  The free energy difference approximation 
(∆∆Gapp) for WO1 binding to each mutant relative to WT fibrils was 
calculated using the equation shown in figure 16.  These values were 
plotted on the bar graph with the error bars showing the standard 
deviation between replicates.  In this figure, a higher, positive ∆∆Gapp 
indicates that WO1 binds more strongly to the particular alanine 




may be more favorable in this position to the packing of the amyloid 
core.  This may, in turn, stabilize the epitope recognized by WO1.  The 
large difference in binding affinity suggests that residue 27 is very 
important in WO1 binding to Aβ amyloid. 
 
The K28A mutant fibrils were bound much more strongly with a 
∆∆Gapp value around 1.5 kcal/mol.  This amounts to about ten times 
stronger binding compared to wild-type fibrils.  The alanine is 
hydrophobic and is much smaller than the positively-charged lysine.  
The enhanced binding to these fibrils may stem from a net reduction in 
positive charge of the fibrils.  The less positive charge may be more 
favorable to anti-amyloid antibody binding.  However, considering the 
results at residue 27, the charge difference may be less important.  
Since residue 28 is directly beside residue 27, it may be affected in a 
similar manner though to a lesser degree than residue 27.  The alanine 
may be better suited to packing simply because of the smaller size of 
the side group. 
 
 The PGA1 binding results followed a similar pattern to the WO1 
results (Figure 21).  The N27A mutant fibrils were bound even more 





















Figure 21.  Summary of PGA1 binding to alanine mutants of Aβ.  
Data is in duplicate.  From the binding curves (not shown), the binding 
affinity of PGA1 for each mutant fibril was calculated.  The free energy 
difference approximation (∆∆Gapp) for PGA1 binding to each mutant 
relative to WT fibrils was calculated using the equation shown in figure 
16.  These values were plotted on the bar graph with the error bars 
showing the standard deviation between replicates.  In this figure, a 
higher, positive ∆∆Gapp indicates that PGA1 binds more strongly to the 
particular alanine mutant than to WT. 
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about ninety times stronger binding compared to wild-type fibrils 
(Figure 18b).  This is three times the ratio demonstrated by WO1.  The 
K28A mutant fibrils were bound comparably at a ∆∆Gapp value of 
around 1.6 kcal/mol.  This suggests that residues 27 and 28 carry a 
similar importance to both WO1 and PGA1 binding, but residue 27 
appears to be even more critical in PGA1 binding. 
 
PGA1 Binding to Cysteine and Modified Cysteine Mutants of Aβ 
Among the mutant Aβ amyloid fibrils available in our lab are a 
series of single cysteine mutants.  In addition to these fibrils are two 
sets that have been modified at the cysteine residue.  These exploit 
the fact that the wild-type Aβ sequence contains no cysteines (Figure 
3).  One set was modified with the addition of an acetic acid group by 
reaction of the cysteine with iodoacetic acid (IAA).  These are 
carboxymethylthio-modified (CMT) fibrils.  The other set was modified 
with the addition of a methyl group by reaction of the cysteine with 
methyl iodide (MeI).  These are methylthio-modified (MT) fibrils.  All 
three sets of fibrils are products of the work of Dr. Shankaramma 
Shivaprasad.  The CMT-modification provides a negatively charged 
group at the residue while the MT-modification provides a hydrophobic 
group.  Since these modifications should not alter fibril structure to the 
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degree that proline does, testing antibody binding to these fibrils 
should be more telling as to the impact of local changes on antibody 
binding.  These experiments were run to get more insight into the 
involvement of individual residues in antibody binding.  They act as a 
supplement to the alanine mutant data.  None of the three sets of 
fibrils are complete, so only a few selected mutants were tested (Table 
3).  PGA1 was the anti-amyloid antibody used in this work.  
Accordingly, the cysteine mutant binding results were interpreted in 
relation to the other PGA1 binding results. 
 
Binding was tested to all three modified cysteine mutant fibrils at 
residue 36 (valine in wild-type) due to its prominence in the proline 
mutant data.  There did not seem to be much difference in binding to 
any of these fibrils or wild-type, suggesting that local changes at this 
residue are less important (Table 3).  Binding was tested to all three 
modified cysteine mutant fibrils at residue 28 and to unmodified 
cysteine mutant fibrils at residue 16 because these residues are 
lysines in wild-type Aβ (Figure 3).  The modified mutant fibrils for 
residue 16 were not available.  Since lysine is a positively charged 
residue at physiological pH, these experiments were intended to 
observe the effect of removing or reversing this charge on PGA1  
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Table 3.  PGA1 binding to cysteine mutant fibrils.  This table 
shows the affinity of PGA1 for each mutant and for WT fibrils (run on 
the same plate on the same day).  These data are in single replicates.  
From the binding curves (not shown), the binding affinity of PGA1 for 
each mutant fibril was calculated.  The free energy difference 
approximation (∆∆Gapp) for PGA1 binding to each mutant relative to WT 
fibrils was calculated using the equation shown in figure 16.  These 
values are shown in the next to last column.  Fibril stability is shown in 
the last column.  Fibril stability is expressed as a free energy 
difference (∆∆G) of fibril formation between the mutant and WT fibrils 
[34].  These values were calculated from the critical concentrations, 
the molar concentration of soluble peptide present at equilibrium, of 
the fibrils [34].  A positive ∆∆G value indicates that the mutant is less 
stable than WT.  The two most dramatic differences are bold and 















K16C 16 12 -0.18 0.42 
K28C 3.6 20 1.06 0.89 
I31C 20 41 0.44 1.47 
I32C 25 20 -0.14 2.18 
Cysteine 
mutant 
V36C 9.6 12 0.14 1.73 
K28C 22 20 -0.06 1.56 
A30C 0.44 41 2.79 1.67 
I31C 3.5 41 1.52 1.75 





V36C 17 12 -0.21 2.66 
D23C 32 20 -0.29 -0.23 
K28C 8.7 20 0.51 0.29 
A30C 20 41 0.44 0.34 





V36C 12 12 0.00 1.84 
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binding.  These fibrils gave much the same PGA1 binding results as 
wild-type aside from a moderate binding improvement for the 
unmodified cysteine mutant at residue 28 (Table 3).  Removal of the 
positive charge at residue 28 appears to have a positive impact on 
PGA1 binding as seen for the K28C and K28C-MT fibrils.  However, a 
charge reversal due to CMT-modification eliminates the enhanced 
binding (Table 3).  The most interesting results from this work came 
from PGA1 binding to the CMT-modified fibrils at residues 30 and 31 
(alanine and isoleucine in wild-type).  PGA1 binding to CMT-modified 
A30C and I31C was quite good with ∆∆Gapp values around 2.8 kcal/mol 
and 1.5 kcal/mol, respectively.  These represent roughly ninety- and 
ten-fold improved PGA1 binding affinity (Table 3, Figure 18b).  
Replacement of these hydrophobic groups with a negatively charged 
group seems to be beneficial to binding.  In comparison, replacement 
with the hydrophobic methyl group yielded little change in binding 
affinity as seen in the binding results to the MT-modified fibrils (Table 
3).  From these data, it appears that PGA1 binding to Aβ fibrils is not 
very sensitive to charge differences at residues 16 and 36.  PGA1 
binding appears to be sensitive to charge differences at residues 28, 




 Several characteristics of anti-amyloid antibody binding to fibrils 
were investigated through the aforementioned experiments.  The salt 
effects results suggest that electrostatic interactions are relatively 
important to WO1 binding and hydrophobic interactions are relatively 
unimportant.  The pH results suggest that the interaction between 
WO1 and fibrils is pH-optimized.  This further supports the salt effect 
results since electrostatic interactions are more sensitive to pH than 
hydrophobic interactions.  The WO1 and PGA1 binding results to the 
many different mutant fibrils looked more closely into amyloid fibril 
structure.  None of the sets of mutants were complete, but there were 
several noteworthy findings within the available binding results.  WO1 
binding to K16P fibrils and PGA1 binding to V36P fibrils was greatly 
enhanced.  Both WO1 and PGA1 binding to N27A and K28A fibrils were 
significantly enhanced.  PGA1 binding to A30C-CMT and I31C-CMT 
fibrils was considerably enhanced while binding to K28C was 
somewhat enhanced.  These are the highlights of the results, but 
much more information was made clear through comparisons of the 
binding data to other available data. 
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An issue mentioned in the results was that WO1 and PGA1 bound 
comparably or better to most of the mutant fibrils compared to wild-
type fibrils.  This was somewhat unexpected since one would presume 
the antibodies would bind significantly less strongly to at least some of 
the mutant fibrils.  A possible explanation for this bias could relate to 
fibril stability.  Most of the proline [34] and alanine (Angela Williams, 
unpublished data) mutant fibrils were destabilized compared to wild-
type fibrils.  It could be that the antibodies are better able to bind 
destabilized fibrils.  This relationship could be considered in terms of 
the fibril superstructure.  Mutations causing fibril destabilization could 
weaken the association of the protofilaments.  This could result in 
these protofilaments coming unwound at fibril ends like the frayed 
ends of a rope.  Frayed fibril ends could make the antibody binding 
sites more accessible.  The fibril stability data were compared to the 
antibody binding data to look for any potential correlation (Figure 22, 
Table 4).  Antibody binding data were plotted versus fibril stability and 
best fit lines were determined (Figure 22).  Many different 
comparisons were made, but no correlation was found between any 
set of binding data and fibril stability (Table 4).  It is possible that fibril 
stability plays a role in antibody binding, but it does not appear to be 
the dominant factor.  A closer look at the data shows some overlap  
WO1 and PGA1 binding to all mutant fibrils
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Figure 22.  Comparison plots of antibody binding to fibril 
stability.  These plots are examples of the comparisons done for 
antibody binding versus fibril stability.  A best fit line was plotted for 
each set of data and a correlation coefficient (R^2) found.  The first 
plot shown involves both WO1 and PGA1 binding to all the available 
mutants including proline, alanine, and cysteine mutants.  The other 







Table 4.  Comparison table of antibody binding to fibril stability.  
The first column lists all the different sets of antibody binding data 
compared to different sets of fibril stability data.  The second and third 
columns show the slope and correlation coefficient (R^2) from the 
best fit done for each set of data.  The highest R^2 value was only 
0.14.  None of the comparisons showed any significant correlation. 
Fibril stability comparison Slope R^2 
WO1/PGA1 to all mutants 0.1 0.008 
WO1/PGA1 to all core mutants (15-36) 0.015 0.0003 
WO1/PGA1 to pro mutants 0.18 0.022 
WO1/PGA1 to ala mutants -0.033 0.0013 
WO1/PGA1 to core pro mutants (15-36) 0.029 0.0009 
WO1/PGA1 to core ala mutants (15-36) -0.18 0.067 
WO1 to pro/ala mutants 0.024 0.0004 
PGA1 to pro/ala mutants 0.14 0.019 
WO1 to core pro/ala mutants (15-36) -0.095 0.0087 
PGA1 to core pro/ala mutants (15-36) 0.069 0.0073 
WO1 to pro mutants 0.031 0.0005 
PGA to pro mutants 0.32 0.071 
WO1 to ala mutants -0.052 0.0027 
PGA1 to ala mutants -0.02 0.0006 
WO1 to core pro mutants (15-36) 0.095 0.0054 
PGA to core pro mutants (15-36) 0.21 0.045 
WO1 to core ala mutants (15-36) -0.28 0.14 
PGA1 to core ala mutants (15-36) -0.083 0.018 
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Between them (Figure 23).  For the proline mutant fibrils, the data 
overlap at residues 15, 16, 27, and generally 33 to 36 (Figures 23a & 
b).  For the alanine mutant fibrils, the data overlap at residues 27 and 
28 (Figures 23c & d).  These data include the mutant fibrils to which 
the antibodies bound particularly well.  This suggests that fibril 
stability may have some impact on binding.   
 
Another issue mentioned in the results is the importance of the 
overall charge of the fibril or of certain residues within the Aβ 
sequence.  Considering all the mutant fibril binding data, it appears 
that less positively charged or more negatively charged fibrils are 
often bound better by the WO1 and PGA1 antibodies.  This is 
evidenced by anti-amyloid antibody binding to the K16P, K28A, K28C, 
A30C-CMT, and I31C-CMT mutant Aβ fibrils.  This is not always the 
case such as for PGA1 binding to K16P, K16C, and K28C-CMT mutant 
fibrils and for WO1 binding to K16A fibrils.  Nonetheless, the charge of 
these residues appears to have a strong impact on anti-amyloid 
antibody binding.  A comparison of the antibody binding data to 
hydrophobicity change data was employed to further investigate these 
results [46].  The binding data were compared to the change in 










































Figure 23.  WO1 and PGA1 binding to proline and alanine 
mutant fibrils versus fibril stability.  The binding data were plotted 
alongside proline and alanine mutant fibril stability data.  A positive 
fibril stability value indicates that the mutant is destabilized compared 
to WT fibrils.  A positive ∆∆Gapp value for antibody binding indicates the 











































Figure 23.  Continued. 
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either proline or alanine.  The hydrophobicity change data are based 
on water/octanol partitioning of individual amino acids [46], so they 
only approximate the change in the Aβ peptide.  The hydrophobicity 
change data were compared to the antibody binding data to look for 
any potential correlation (Figure 24, Table 5).  Antibody binding data 
were plotted versus hydrophobicity change and best fit lines were 
determined (Figure 24).  Many different comparisons were made, but 
no correlation was found for any of them (Table 5).  This suggests that 
WO1 and PGA1 binding do not correlate simply with the bulk 
hydrophobicity or hydrophilicity of amyloid fibrils.  However, there 
does appear to be some correlation at certain residues.  WO1 binding 
data to the proline mutant fibrils coincides with the hydrophobicity 
change data significantly at residues 16, 33, and 37 (Figure 25a).  
Residue 16 was expected to stand out due to the positive charge and 
highly hydrophilic nature of lysine.  There was no correlation at residue 
28, the other lysine to proline mutation.  Perhaps substituting a rigid 
proline at position 28 alters the fibril structure unfavorably for WO1 
binding.  Residues 33 and 37 are both glycines in wild-type Aβ.  
Glycine is a somewhat hydrophilic, uncharged residue.  WO1 may bind 
more strongly to these mutants because of the increased 
hydrophobicity or it may do so because of the significant structural  
WO1 and PGA1 binding to all mutant fibrils
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Figure 24.  Comparison plots of antibody binding to 
hydrophobicity change.  These plots are examples of the 
comparisons done for antibody binding versus hydrophobicity change.  
A best fit line was plotted for each set of data and a correlation 
coefficient (R^2) found.  The first plot shown involves both WO1 and 
PGA1 binding to all the available proline and alanine mutant fibrils.  








Table 5.  Comparison table of antibody binding to 
hydrophobicity change.  The first column lists all the different sets 
of antibody binding data compared to different sets of hydrophobicity 
change data.  The second and third columns show the slope and 
correlation coefficient (R^2) from the best fit done for each set of 
data.  The highest R^2 value was only 0.25.  None of the comparisons 
showed any significant correlation. 
Hydrophobicity comparison Slope R^2 
WO1/PGA1 to pro/ala mutants 0.36 0.02 
WO1/PGA1 to core pro/ala mutants (15-36) 0.32 0.017 
WO1/PGA1 to pro mutants -0.15 0.0042 
WO1/PGA1 to ala mutants 1.05 0.18 
WO1/PGA1 to core pro mutants (15-36) -0.26 0.013 
WO1/PGA1 to core ala mutants (15-36) 1.04 0.22 
WO1 to pro/ala mutants 0.47 0.028 
PGA1 to pro/ala mutants 0.32 0.017 
WO1 to core pro/ala mutants (15-36) 0.48 0.03 
PGA1 to core pro/ala mutants (15-36) 0.23 0.011 
WO1 to pro mutants 0.46 0.026 
PGA to pro mutants -0.62 0.067 
WO1 to ala mutants 1.11 0.17 
PGA1 to ala mutants 1.01 0.2 
WO1 to core pro mutants (15-36) 0.53 0.034 
PGA to core pro mutants (15-36) -0.84 0.14 
WO1 to core ala mutants (15-36) 1.1 0.2 






















































Figure 25.  WO1 and PGA1 binding to proline and alanine 
mutant fibrils versus hydrophobicity change.  The antibody 
binding data were plotted alongside hydrophobicity change data.  The 
hydrophobicity change data are based on water/octanol partitioning of 
amino acids [46].  To calculate the change in hydrophobicity for each 
mutant, the hydrophobicity value for either proline or alanine was 
subtracted from that for the WT residue.  A positive hydrophobicity 
change value indicates increased hydrophobicity.  A positive ∆∆Gapp 
value for antibody binding indicates the antibody bound more strongly 






















































Figure 25.  Continued. 
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change between the very flexible glycine and the rigid proline.  The 
PGA1 binding data to the proline mutant fibrils coincides with the 
hydrophobicity change data at residues 16, 28, and 33 (Figure 25b).  
Residues 16 and 28 were expected to stand out since they are both 
lysines in wild-type fibrils.  Residue 33 may stand out for the same 
reasons discussed for WO1 binding.  These results are revealing, but 
the limitation that proline can substantially alter fibril structure must 
be considered for these fibrils. 
 
A comparison of antibody binding to hydrophobicity changes for 
alanine mutant fibrils could be more informative since alanine should 
not cause substantial structural changes.  The WO1 and PGA1 binding 
data to these fibrils coincides significantly with the hydrophobicity 
change data only at residue 28 (Figures 25c & d).  This suggests that 
both antibodies bind more strongly to fibrils that are more hydrophobic 
at this residue.  The PGA1 binding data to the cysteine and modified 
cysteine mutants at residue 28 support this notion (Table 3).  There 
was enhanced PGA1 binding to the more hydrophobic K28C and K28C-
MT fibrils, but not to the negatively charged K28C-CMT fibrils.  These 
results are further supported by studies of accessibility of cysteine 
mutant fibrils to alkylation by iodoacetic acid (Dr. Shankaramma 
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Shivaprasad, unpublished data).  These studies showed residue 28 to 
be inaccessible to solvent, suggesting it is buried in the amyloid core.  
If this is the case, a hydrophobic amino acid at this residue could 
potentially stabilize the epitopes recognized by the antibodies.  
Residues 16, 33, and 37 do not show a strong correlation as is seen 
with the proline mutants (Figures 25c & d).  This suggests that the 
improved binding to the proline mutant fibrils at these residues may 
be due to structural changes rather than simply increased 
hydrophobicity.  In the case of residue 16, it may be due to structural 
changes rather than the removal of the positive charge. 
 
 The results for PGA1 binding to several mutants at residue 28 
initially seem to run counter to the salt and pH effects experiments 
(Figure 25, Table 3).  The antibodies appear to prefer that residue 28 
is hydrophobic.  This would suggest that the antibodies bind through 
hydrophobic interactions.  However, residue 28 appears to be buried in 
the amyloid core.  Furthermore, PGA1 binding to mutants of residues 
30 and 31 suggests electrostatic interactions are more important 
(Table 3).  There was greatly enhanced PGA1 binding to the negatively 
charged A30C-CMT and I31C-CMT mutant fibrils, but not to the 
unmodified or MT-modified fibrils.  These results suggest PGA1 may 
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rely more on electrostatic interactions.  It is still likely that the binding 
of PGA1 to fibrils is not entirely dependant on electrostatic 
interactions.  Nonetheless, PGA1 binding appears to be more 
dependant upon electrostatic interactions. 
 
There are many cases of enhanced antibody binding not 
attributable to just charge or stability differences.  These include WO1 
binding to K16P and PGA1 binding to V36P fibrils (Figures 23 & 25).  In 
these cases, charge was not found to be important and fibril stability 
was not drastically higher or lower than many mutant fibrils that were 
bound less strongly by the antibodies.  There may be specific 
structural changes to these fibrils that make the antibody epitopes 
more accessible or more favorable to the antibodies.  For K16P and 
V36P, one possible explanation is that the rigid proline could serve to 
secure the unstructured amino- or carboxy-terminus such that it 
cannot fold back onto the amyloid core.  This may allow better 
antibody access to the fibril surface.  The enhanced binding of WO1 
and PGA1 to N27A fibrils was unexpected.  It does not appear to be 
attributable to either a charge difference or a large stability difference 
(Figures 23 & 25).  These fibrils are destabilized, but not appreciably 
more or less than many fibrils that were bound much less strongly by 
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the antibodies.  It appears that both WO1 and PGA1 binding are very 
sensitive to changes at this residue.  It could be that the structural 
change, however small, imparted by substituting alanine for 
asparagine stabilizes the epitopes recognized by the antibodies. 
 
Another available set of data to which antibody binding can be 
compared is ThT binding.  These data were collected during the 
monitoring of fibril growth progress for all of the mutant fibrils (Angela 
Williams) [34].  The level of ThT binding is measured to detect the 
amount of fibrils in a sample.  Eventually, a maximal level of ThT 
binding is obtained.  This value is corrected based on the starting and 
ending concentrations of Aβ monomer in a sample.  The reason for this 
correction is that ThT is measured on a fibril suspension that contains 
varying percentages of fibrils, depending on the fibril stability 
conferred by the mutation.  ThT signal can be attributed to multiple 
possible effects: ThT binding affinity, ThT binding site number, and/or 
ThT fluorescent yield.  It may be a combination of these three factors 
affecting binding.  This should be kept in mind when comparing the 
antibody and ThT binding data.  These two sets of data were compared 
to look for any potential correlation between them (Figure 26, Table 
6).  Antibody binding data were plotted versus ThT binding data and  
WO1 and PGA1 binding to all mutant fibrils
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Figure 26.  Comparison plots of antibody binding to ThT 
binding.  These plots are examples of the comparisons done for 
antibody binding versus ThT binding.  A best fit line was plotted for 
each set of data and a correlation coefficient (R^2) found.  The first 
plot shown involves both WO1 and PGA1 binding to all the available 
proline and alanine mutant fibrils.  The other two plots make more 







Table 6.  Comparison table of antibody binding to ThT binding.  
The first column lists all the different sets of antibody binding data 
compared to different sets of hydrophobicity change data.  The second 
and third columns show the slope and correlation coefficient (R^2) 
from the best fit done for each set of data.  The highest R^2 value was 
0.42.  None of the comparisons showed a strong correlation. 
ThT fluorescence Slope R^2 
WO1/PGA1 to pro/ala mutants 0.48 0.11 
WO1/PGA1 to core pro/ala mutants (15-36) 0.54 0.15 
WO1/PGA1 to pro mutants 0.36 0.086 
WO1/PGA1 to ala mutants 0.62 0.21 
WO1/PGA1 to core pro mutants (15-36) 0.47 0.13 
WO1/PGA1 to core ala mutants (15-36) 0.61 0.22 
WO1 to pro/ala mutants 0.85 0.25 
PGA1 to pro/ala mutants 0.37 0.12 
WO1 to core pro/ala mutants (15-36) 1.04 0.34 
PGA1 to core pro/ala mutants (15-36) 0.38 0.13 
WO1 to pro mutants 0.55 0.15 
PGA to pro mutants 0.31 0.063 
WO1 to ala mutants 0.62 0.32 
PGA1 to ala mutants 0.54 0.39 
WO1 to core pro mutants (15-36) 0.93 0.33 
PGA to core pro mutants (15-36) 0.33 0.07 
WO1 to core ala mutants (15-36) 0.61 0.29 




best fit lines were determined (Figure 26).  Many different 
comparisons were made, but no strong correlation was found for any 
of them (Table 6).  However, overall the correlations were significantly 
better than for the other attempted comparisons.  There also appeared 
to be correlation at certain residues.  WO1 and ThT binding appeared 
to have numerous connections within the set of proline mutants 
(Figure 27a).  The most prominent of these were at residues 16, 27, 
and 33.  Likewise, residues 16, 27, and 33 stood out notably for PGA1 
binding (Figure 27b).  These residues were earlier suggested to be 
important for antibody binding due to possible structural changes 
rather than to charge or major stability differences.  It is possible that 
ThT binding is similarly affected by these changes.  WO1 and PGA1 
binding to the alanine mutant fibrils appeared to overlap ThT binding, 
particularly at residues 27, 28, and 29 (Figure 27c & d).  These alanine 
mutant fibrils are the most strongly bound by WO1 and PGA1.  They 
also represent three of the four alanine mutants most strongly bound 
by ThT (Figure 27c & d).  There are many parallels between the 
binding of the antibodies and ThT to the alanine mutant fibrils.  As 
such, it is quite possible that the binding sites of the antibodies and 
ThT are related.  It is also possible that ThT and antibody binding both 
correlate with an unknown third variable, such as fibril flexibility or 
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Figure 27.  WO1 and PGA1 binding to proline and alanine 
mutant fibrils versus ThT binding.  The antibody binding data were 
plotted alongside ThT binding data.  The ThT binding data are derived 
from maximal corrected ThT fluorescence data obtained while 
monitoring fibril growth (Angela Williams) [34].  These ThT data were 
prepared for this comparison plot using the equation: (mutant ThT 
fluorescence – WT ThT fluorescence) / WT ThT fluorescence.  The ThT 
data have no units.  A positive ThT fluorescence change indicates 
greater ThT binding by the mutant versus WT fibrils.  A positive ∆∆Gapp 
value for antibody binding indicates the antibody bound more strongly 
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motility.  In any case, there appears to be some connection between 
the binding of the anti-amyloid antibodies and ThT to fibrils. 
 
Antibody binding data were also compared to HD exchange data 
for proline mutant fibrils [34].  These data provide a measure of the 
amount of β-sheet structure since residues not involved in this 
structure are expected to be more susceptible to HD exchange [34].  
Comparing the binding data to these data could give some insight into 
whether antibody binding correlates with the amount of β-sheet 
structure.  These two sets of data were compared (Figure 28, Table 7).  
Antibody binding data were plotted versus HD exchange data and best 
fit lines were determined (Figure 28).  Several comparisons were 
made, but no correlation was found for any of them (Table 7).  This 
suggests that WO1 and PGA1 binding do not correlate with the amount 
of β-sheet structure implied by the HD exchange data. 
 
After examining the antibody binding data and comparing it to 
several other bodies of data, the information was compared to our 
model of the amyloid protofilament (Figure 29a).  In addition, it was 
compared to another model of fibril structure with many differences 
from our model [47] (Figure 29b).  The Tycko model consists of Aβ 
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Figure 28.  Comparison plots of antibody binding to difference 
in protected residues.  These plots are examples of the comparisons 
done for antibody binding versus the number of protected residues 
above WT fibrils.  These numbers were calculated from the data 
presented in [34] using the equation: (40 - # protected residues in 
mutant) - # protected residues in WT.  A best fit line was plotted for 
each set of data and a correlation coefficient (R^2) found.  The first 
plot shown involves both WO1 and PGA1 binding to all the available 







Table 7.  Comparison table of antibody binding to difference in 
protected residues.  The first column lists all the different sets of 
antibody binding data compared to different sets of HD exchange data.  
The second and third columns show the slope and correlation 
coefficient (R^2) from the best fit done for each set of data.  The 
highest R^2 value was 0.071.  None of the comparisons showed any 
correlation. 
HD exchange comparison Slope R^2 
WO1/PGA1 to pro mutants -0.17 0.0054 
WO1/PGA1 to core pro mutants (15-36) -0.38 0.024 
WO1 to pro mutants 0.056 0.0003 
PGA to pro mutants -0.2 0.0087 
WO1 to core pro mutants (15-36) -1.14 0.071 
PGA to core pro mutants (15-36) -0.23 0.011 
 
 
Figure 29.  Two Aβ amyloid protofilament models.  Our model is 
shown in figure A while the Tycko model [47] is shown in figure B.  
(Figure B adapted from Petkova, A.T., et al.,  A structural model for 
Alzheimer's beta -amyloid fibrils based on experimental constraints 




subunits in which there are two β-strands, residues 12 to 24 and 30 to 
40.  The amino terminus is unstructured and residues 25 to 29 
comprise a bend in the sequence [47].  There is also a potential salt 
bridge between residues D23 and K28 in the core of the Tycko model 
(Figure 29b). 
 
The possible explanation for the WO1 binding results to K16P 
could fit into either model.  That is, the rigid proline could serve to 
secure the unstructured amino-terminus such that it does not fold 
back onto the fibril and impede the antibody from binding.  In both 
cases, there is an unstructured amino-terminus, though this terminus 
stops around residues 10 to 12 in the Tycko model (Figure 29b).  The 
results for PGA1 binding to V36P can be similarly explained as this 
residue is near the unstructured carboxy-terminus in our model 
(Figure 29a).  They do not, however, fit as well into the Tycko model 
since it lacks an unstructured carboxy-terminus.  It is possible that 
these results could hinge more on destabilization of the fibril.  If that is 
case, they could fit the Tycko model. 
 
The results for WO1 and PGA1 binding to N27A are less clear.  
The change from an asparagine to an alanine does not result in a 
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charge difference and should not cause large structural changes 
compared to wild-type.  In our model, this residue is in the middle of a 
β-strand whereas in the Tycko model it is in the bend between the two 
β-strands (Figure 29).  The results for residue 27 do not seem to 
exclude either model.  However, they do not seem to clearly support 
one over the other either. 
 
The results for PGA1 binding to the A30C-CMT mutant fibrils 
could fit into either model.  Both models transition from turn to β-
strand structure around this residue.  Being near the turn region, 
charged residues may be tolerated or, as the binding data suggests, 
preferred.  Residue 30 appears to be extremely accessible to solvent 
based on the cysteine mutant fibril alkylation studies (Dr. 
Shankaramma Shivaprasad, unpublished data).  Those results are in 
agreement with both models [34, 47].  The PGA1 binding results to 
the A31C-CMT mutant fibrils are somewhat less clear.  This residue 
appears to be inaccessible to solvent based on the aforementioned 
alkylation studies (Dr. Shankaramma Shivaprasad, unpublished data).  
Furthermore, it is buried in the core of the Tycko model [47].  The 
results do not seem to fit either model.  These fibrils may possess an 
altered structure, such as incorporating residues 30 and 31 into an 
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extended turn, to accommodate a charge at this residue.  It could also 
be the case that the residue is still in the fibril core at the cost of 
reduced fibril stability.  The latter scenario takes into account that 
PGA1 appears to bind more strongly to destabilized fibrils. 
 
 The results for WO1 and PGA1 binding to K28A fibrils seem quite 
clear.  Combined with the PGA1 binding results to modified cysteine 
mutant fibrils, it appears that the antibodies bind more strongly to 
fibrils in which residue 28 is hydrophobic.  Residue 28 appears to be 
buried in the amyloid core, a hydrophobic environment unfavorable to 
lysine.  A more hydrophobic amino acid at this position could 
potentially pack better into the amyloid core.  This could stabilize the 
epitopes recognized by WO1 and PGA1.  The Tycko model has the 
lysine at residue 28 in the amyloid core, but it may form a salt bridge 
with the aspartic acid at residue 23 [47] (Figure 29b).  Residue 23 
appears to be inaccessible to solvent based on the aforementioned 
alkylation studies (Dr. Shankaramma Shivaprasad, unpublished data).  
This lends some support to the Tycko model.  However, the antibody 
binding results to the mutants at residue 28 seem to indicate that if a 
salt bridge exists, it is not critical to the structure of the fibril.  A salt 
bridge may exist in wild-type fibrils, but the K28A mutant may prevent 
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 Several characteristics of anti-amyloid antibody binding to fibrils 
were investigated.  The salt and pH effects results suggest that 
electrostatic interactions are relatively important to WO1 binding and 
hydrophobic interactions are relatively unimportant.  The WO1 and 
PGA1 binding results to the many different mutant fibrils looked more 
closely into amyloid fibril structure.  There were several noteworthy 
findings.  WO1 binding to K16P fibrils and PGA1 binding to V36P fibrils 
was greatly enhanced.  Both WO1 and PGA1 binding to N27A and 
K28A fibrils were significantly enhanced.  PGA1 binding to A30C-CMT 
and I31C-CMT fibrils was considerably enhanced while binding to K28C 
was somewhat enhanced. 
 
Much more information was made clear through comparisons of 
the binding data to other available data.  A comparison of the binding 
data to fibril stability showed no correlation.  Fibril stability could play 
a role in antibody binding, but it does not appear to be the dominant 
factor.  Antibody binding data were compared to hydrophobicity 
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change data, but no correlation was found.  This suggests that WO1 
and PGA1 binding do not correlate with the bulk hydrophobicity or 
hydrophilicity of amyloid fibrils.  Antibody binding data were compared 
to HD exchange data to look for a relationship between the amount of 
β-sheet structure and binding.  No correlation was found, suggesting 
that WO1 and PGA1 binding do not correlate with the amount of β-
sheet structure implied by the HD exchange data.  Comparing antibody 
and ThT binding data to fibrils revealed some weak correlation.  This is 
the most interesting result to come from the correlation studies.  It 
suggests there could be a relationship between binding of the anti-
amyloid antibodies and ThT to fibrils. 
 
With regard to certain residues, there appeared to be more 
correlation.  Fibril stability appears to show some importance to 
antibody binding with regard to certain residues such as 16 and 36.  
Charge also appears to be important considering the results at 
residues 28, 30, and 31.  In addition, some more specific structural 
features appear to be important based on the results at residues 16, 
27, and 36.  It looks as if the binding of these antibodies and ThT to 
amyloid fibrils are related based on some correlation in the data 
overall and some overlap in the binding results to specific mutants.  It 
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does not appear that antibody binding correlates with the amount of β-
sheet structure implied by the HD exchange data.  Lastly, the binding 
results agree, for the most part, with our model of Aβ amyloid.  
Mutations in the Aβ sequence have a strong impact on binding of the 
anti-amyloid antibodies.  The basis of these results is still not clear, 
but they could be important clues to the nature of fibril structure or at 
least the fibril epitopes recognized by the antibodies. 
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Chapter IV 
Phage Display Results and Discussion 
 
 
 The available anti-amyloid antibodies are all of the IgM class 
(Figure 5e).  As mentioned earlier, these are large, flexible, 
multivalent species not amenable to many structural studies.  For 
example, the large size and flexibility of IgM molecules is very 
unfavorable to protein crystallography.  Another example is the 
multivalent and cooperative nature of IgM binding to antigens 
complicates potential mutagenesis studies because a single mutation 
affects all ten binding sites.  One potential option is to study fragments 
of these IgM antibodies.  However, it was shown that monovalent 
fragments of WO2 do not bind any better to Aβ fibrils than to BSA 
(Figure 14).  It would be preferable to study fragments with significant 
affinity for amyloid fibrils.  Due to the limitations of the available 
antibodies, phage display experiments were carried out with the goal 
of producing anti-amyloid antibody fragments.  Some progress was 
made to this end. 
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Verification of Phage Production and Anti-M13 Antibody 
Specificity 
 The phagemid clone received from the Barbas laboratory was 
transformed into XL1-Blue E. coli cells.  A culture of the transformed 
cells was grown up and infected with helper phage to produce clonal 
phage particles.  These were purified for use in a preliminary phage 
ELISA.  This experiment was conducted to determine three things: if 
the phage production protocol generates a suitable phage titer, if the 
phage clone is bound by the chosen anti-M13 biotin secondary 
antibody, and if there is any significant background binding of the 
secondary antibody to Aβ amyloid.  There appeared to be a suitable 
phage titer and strong binding by the secondary antibody.  This is 
evidenced by the substantial binding curve for anti-M13 antibody to 
the phage clone (Figure 30).  There is essentially no background 
binding of anti-M13 antibody to Aβ amyloid evidenced by a flat curve 
(Figure 30). 
 
Phage Library Production 
To generate the initial phage library, PCR random mutagenesis 
was carried out on the Fab genes within the phagemid clone.   As 
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Figure 30.  Verification of anti-M13 Ab specificity.  The blue 
diamond marked curve shows that the purified phage clone is bound 
by the anti-M13 antibody.  The magenta square marked curve is a 
positive control to verify the activity of the anti-M13 antibody on 
immobilized phage.  The green triangle marked curve shows the lack 




primer (Table 2) to determine the rate of mutagenesis.  The rate of 
base mutation was found to be roughly 1.5%.  The phagemid library 
was transformed into XL1-Blue E. coli cells.  Three rounds of selection 
against Aβ amyloid were conducted in hopes of enriching phage 
capable of binding the fibrils.  The input and output phage titers at 
each stage of panning were determined.  The phage titer after 
transformation of the starting library was 5*10^8 pfu/mL.  For pan 1, 
the titers were 3*10^12 pfu/mL input and 2*10^7 pfu/mL output.  
For pan 2, the titers were 8*10^11 pfu/mL input and 8*10^2 pfu/mL 
output.  For pan 3, the titer could not be determined since all of the 
plates were blank, including the input titer plates.  Phage pools from 
each round of selection as well as a nonpanned, preselection pool were 
saved for a total of four phage pools. 
 
 To test the phage pools for the presence of Aβ amyloid binding 
clones, several phage ELISA experiments were performed.  All four 
phage pools were tested using the anti-M13 phage antibody as the 
secondary antibody.  These experiments were not meant to be used 
for determining binding activity, but just to confirm whether or not 
there is any significant binding at all.  This is indicated by a higher, 
right-shifted curve for aggregate binding compared to background 
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binding to BSA.  The phage ELISAs indicated that all the phage pools 
possessed the ability to bind Aβ amyloid (Figure 31).  This was 
unexpected since even the nonpanned phage pool appeared to possess 
affinity to Aβ amyloid fibrils (Figure 31, top left).  These results 
indicate that there are a large number of binders even before 
selection.  Antigen-binding sites are normally formed from the CDRs, 
but random mutagenesis should not favor these regions over the rest 
of the sequence.  The majority of the mutants are likely structurally 
altered with truncations and mutations in antibody framework regions.  
Considering the markedly better affinity of the nonpanned library for 
fibrils over BSA blocked wells, it is possible that much of the binding 
came from such structurally altered antibodies.  This suggests there 
could be considerable nonspecific binding.  Phage ELISAs were also 
conducted against polyglutamine aggregates and the phage pools were 
found to have an affinity for them as well (Figure 31, bottom).  Again, 
this may be due to nonspecific binding.  Clones were ultimately 









































































































Figure 31.  Phage pool ELISAs.  ELISA binding assays were 
conducted using phage pools in place of the primary antibody. Even 
the nonpanned pool shows Aβ amyloid binding (top left).  There is also 
binding to polyglutamine aggregates, even though the library was 
selected against Aβ amyloid (bottom). 
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Phage Clone Selection 
The cultures from which the phage pools were collected were 
plated and several clones were selected from each.  Cultures were 
inoculated with picked colonies and grown up to produce clonal phage 
particles.  The same was done for the unmutated phage.  Phage 
ELISAs were carried out for each to determine if any of these 
individual clones could bind Aβ amyloid.  Including the unmutated 
clone, 25 clones were tested for Aβ amyloid binding and 6 clones for 
polyglutamine aggregate binding.  10 clones from the nonpanned pool, 
10 from the first panning, 2 from the second panning, and 2 from the 
third panning were tested for binding to Aβ amyloid.  2 of 25 bound Aβ 
amyloid more strongly than BSA: clones 1-1 and 2-2 (Figure 32).  4 of 
6 drawn from the same set of clones bound polyglutamine aggregates 
more strongly than BSA: clones 1-1, 2-1, 2-2, and 3-1 (Figure 33).  
The unmutated clone did not bind either aggregate very well, 
especially when compared to the clones in figure 33.  The problem 
with most of the clones binding to Aβ amyloid was that their binding to 
BSA was comparable (Figure 32, bottom right).  With the 
polyglutamine aggregates, this was not an issue.  Four clones were 
selected for further work.  These are designated 1-1, 2-1, 2-2, and 3-





















































































Figure 32.  Phage clone binding to Aβ amyloid fibrils.  The 
unmutated clone showed essentially no binding.  Clones 1-1 and 2-2 
are the only two positive clones obtained.  Clone 3-2 is an example of 
one of the rejected clones.  For this clone and most of the other 
negative clones there was often binding to Aβ amyloid, but there was 
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Figure 33.  Phage clone binding to polyglutamine aggregates.  
ELISA binding curves using phage clones in place of the primary 
antibody.  The top 3 curves are for Aβ amyloid binding and the bottom 




taken.  For example, clone 2-1 is from the second panning pool.  
Clones 1-1 and 2-2 bound to both Aβ amyloid and polyglutamine 
aggregates (Figures 32 and 33).  Clones 2-1 and 3-1 bound to 
polyglutamine aggregates only (Figure 33).  The amino acid sequences 
of these clones were examined to look for any differences from the 
original, unmutated clone. 
 
Antibody Clone Sequences 
Cultures were grown up for each clone, including the unmutated 
clone.  Plasmid preparations were performed and the plasmids were 
sent off for sequencing using the OMPSEQ and PELSEQ primers (Table 
2).  The DNA sequences were translated to amino acid sequences.  
The heavy and light chain amino acid sequences for the clones are 
shown in tables 8 and 9, respectively.  It is clear from the data that 
most of the clones are actually truncation mutants.  The clone 2-1 
heavy chain sequence is the only one besides the unmutated heavy 
and light chains that is not truncated (Tables 8 and 9).  It actually has 
an identical amino acid sequence to that of the unmutated heavy 
chain.  Two sequences were truncated as a result of a stop codon 
introduced by a substitution mutation: clone 1-1 heavy chain and 
clone 3-1 light chain.  Three sequences were truncated as a result of 
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Table 8.  Clone heavy chain sequences.  Only the clone 2-1 heavy 
chain lacks a truncation mutation.  Clone 2-2 appeared to actually be 
multiple clones by examining the electropherogram (data not shown).  
Therefore, the clone 2-2 sequence data could not be translated.  
















































Table 9.  Clone light chain sequences.  All the clones were 
apparently truncation mutants.  Clone 2-2 appeared to actually be 
multiple clones (data not shown).  Residues differing from unmutated 





























insertions or deletions causing frameshifts that subsequently led to 
premature stop codons:  3-1 heavy chain, 1-1 light chain, and 2-1 
light chain.  The clone 2-2 heavy and light chain sequences could not 
be accurately translated.  An examination of the electropherograms of 
these two sequences revealed numerous occurrences of overlapping 
base peaks (data not shown).  This suggests there is more than one 
clone in the clone 2-2 sample. 
 
Unfortunately, not all the clone sequences appear to agree with 
the binding results.  The clone 1-1 and 3-1 heavy chains are both 
truncated (Table 8).  This has been verified by obtaining these 
sequences a second time.  The downstream gp3 segment of these 
fusion proteins are, as a result, not expressed (Figure 11).  Lacking 
this segment, the antibody fragment would not be associated with the 
phage particle and should not have an impact on phage selection.  
Since phage expressing these clones appeared to bind amyloid, it 
seems that the phage clones could be binding nonspecifically.  Clones 
1-1 and 3-1 are apparently false positives.  Though the 2-1 light chain 
is truncated due to a frameshift mutation, the heavy chain is intact.  
This clone could be detected via an anti-HA western blot.  Soluble 
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 Fresh E. coli cultures expressing each phagemid were 
grown up and plasmid preps were used to purify the clonal phagemid 
DNA.  These phagemid were electroporated into TOP10 E. coli cells in 
order to carry out expression of soluble Fab protein.  Whole protein 
extracts were taken from cultures of these clones and tested for the 
presence of Fab protein using western blots.  Two monoclonal anti-HA 
antibodies were used in one set of western blot experiments and a 
polyclonal anti-human heavy and light chain antibody in another.  The 
anti-HA western blot results lined up with the sequencing results 
(Figure 34).  As expected, only the two clones possessing the HA tag, 
the unmutated clone and clone 2-1, showed up on these blots.  
Cultures expressing the clones were grown up for protein extraction 
and western blots several times, but these clones did not show strong 
bands on every blot.  In figure 34, the umutated clone showed 
stronger bands in blot A while clone 2-1 showed a stronger band in 
blot B.  It may be that the Fab fragments are not stably expressed 





Figure 34.  Anti-HA western blots.  The lanes in western A are as 
follows:  1) anti-HA IgG, 2) blank, 3) unmutated, 4) clone 3-1, 5) 
clone 2-2, 6) clone 2-1, 7) clone 1-1, 8) unmutated from another 
culture, 9) untransformed, 10) Seeblue Plus 2 MW standard 
(Invitrogen).  The lanes in western B are as follows: 1) clone 2-1, 2) 
unmutated, 3) human IgG, 4) clone 3-1, 5) clone 2-2, 6) clone 2-1, 7) 
clone 1-1, 8) unmutated from another culture, 9) same as lane 8, 10) 











located at the carboxy-terminus of the heavy chain could have been 
cleaved before loading the samples onto the gels.  For the unmutated 
and 2-1 clones, the strong band was at approximately the correct 
molecular weight to represent a heavy chain Fd fragment, around 25 
kDa (Figure 34).  There were different background bands in each of 
these two blots.  This may be due to the different anti-HA antibodies 
used. 
 
The anti-human IgG (heavy and light chain specific) western blot 
showed bands around 25 kDa for some of the clones (Figure 35).  
There were also bands near the gel front for all the clones.  The latter 
bands may represent truncated or partially degraded light and heavy 
chain fragments.  The blot in figure 34b was run alongside that in 
figure 35, but the results were not consistent.  The band near 25 kDa 
for clone 2-1 was very faint.  Furthermore, this band was present for 
clone 3-1, a truncation mutant that should not have it.  The anti-
human IgG western blot results were not consistent.  However, the 
anti-HA western blot results show that if an intact clone is available, 




Figure 35.  Anti-human IgG (heavy and light chain specific) 
western blot.  The lanes in the western are as follows: 1) clone 2-1, 
2) unmutated, 3) human IgG, 4) clone 3-1, 5) clone 2-2, 6) clone 2-1, 
7) clone 1-1, 8) unmutated from another culture, 9) same as lane 8, 





 Initial phage ELISA results suggested that the phage libraries, 
including nonpanned, had an affinity for amyloid fibrils.  However, an 
examination of sequences of selected positive clones revealed that the 
phage selection procedure was ineffective.  All the clones possessed 
truncations in the antibody heavy chain, the light chain, or both.  This 
suggests that these clones were binding nonspecifically.  The 
unmutated clone and clone 2-1 were expressed as soluble fragments, 
but were not purified for further analysis.  Further work will need to be 
done to obtain anti-amyloid Fab fragments. 
 
A successful strategy for obtaining truly positive clones could 
include a step to select for those phage presenting intact Fab 
fragments.  One way to do this could be to include an additional 
selection step in which the phage are incubated in ELISA wells coated 
with anti-Fab antibodies.  That is, after the selection step against 
amyloid, the library could be reamplified and subjected to Fab 
selection before continuing with the next round.  This step could enrich 
the library with clones presenting intact Fab fragments and reduce the 
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1% BSA in 1xPBS: 
 
1 g  BSA (Sigma) 
100 mL 1xPBS (Fisher) 
 





140 mM NaCl, 10 mM Na2PO4, 2.2 mM KH2PO4, 2.7 mM KCl 
 
Order from Fisher as a pre-weighed powder.  Mix into 1L water and 




cell suspension buffer: 
 
2.5 mL 0.2 M EDTA, pH 8.0 (Sigma) 
2.5 mL 1.0 M Tris, pH 7.5 (Sigma) 
95 mL water 
 
 
ELISA blocking solution: 
 
1 g  BSA 
100 mL 1xPBS 
50 µL  Tween20 (Fisher) 
 
 
ELISA wash buffer: 
 
500 mL 1xPBS 








8 g  Difco LB agar (Beckton Dickinson) 
 
Add water to 250 mL final volume.  Autoclave for 20 minutes at 15 psi.  
Let cool to about 45°C.  Pour about 25 mL into each plate and allow 





Prepare LB agar, but do not immediately pour into plates after cooling 
to 45°C.  Add tetracycline (Sigma) to a final concentration of 12 






Prepare LB agar, but do not immediately pour into plates after cooling 
to 45°C.  Add carbenicillin (Sigma) to a final concentration of 50 




25% PEG-8000 / 15% NaCl: 
 
25 g  PEG-8000 (Sigma) 
15 g  NaCl 
 
Add water to 100 mL final volume.  Stir on a hot plate to dissolve 





5 g  MOPS (Sigma) 
15 g  tryptone (Fisher) 
10 g  yeast extract (Beckton Dickinson) 
 
Add water to 500 mL final volume.  Adjust pH to 7.0 with sodium 






1 g  tryptone 
0.25 g yeast extract 
0.025 g NaCl 
9.3 mg KCl 
 
Add water to 50 mL final volume.  Adjust pH to 7.0 with sodium 
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